docs/_posts/2019-04-30-pos_clinical_en.md
docs/_posts/2019-06-04-deidentify_rb_en.md
docs/_posts/2020-01-28-embeddings_clinical_en.md
docs/_posts/2020-01-28-ner_crf_en.md
docs/_posts/2020-01-30-assertion_dl_en.md
docs/_posts/2020-01-30-assertion_ml_en.md
docs/_posts/2020-01-30-ner_bionlp_en.md
docs/_posts/2020-01-30-ner_clinical_en.md
docs/_posts/2020-01-31-clinical_deidentification_en.md
docs/_posts/2020-02-01-clinical_analysis_en.md
docs/_posts/2020-03-25-ner_diseases_en.md
docs/_posts/2020-03-25-ner_drugs_en.md
docs/_posts/2020-03-26-embeddings_healthcare_en.md
docs/_posts/2020-03-26-ner_healthcare_en.md
docs/_posts/2020-04-15-ner_posology_en.md
docs/_posts/2020-04-17-spellcheck_clinical_en.md
docs/_posts/2020-04-21-chunkresolve_cpt_clinical_en.md
docs/_posts/2020-04-21-chunkresolve_icd10cm_clinical_en.md
docs/_posts/2020-04-21-chunkresolve_icd10pcs_clinical_en.md
docs/_posts/2020-04-21-chunkresolve_icdo_clinical_en.md
docs/_posts/2020-04-21-ner_posology_small_en.md
docs/_posts/2020-04-22-ner_anatomy_en.md
docs/_posts/2020-04-22-ner_cancer_genetics_en.md
docs/_posts/2020-04-22-ner_cellular_en.md
docs/_posts/2020-04-22-ner_jsl_en.md
docs/_posts/2020-04-22-ner_jsl_enriched_en.md
docs/_posts/2020-04-22-ner_risk_factors_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_diseases_clinical_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_injuries_clinical_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_musculoskeletal_clinical_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_neoplasms_clinical_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_poison_ext_clinical_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_puerile_clinical_en.md
docs/_posts/2020-05-16-chunkresolve_loinc_clinical_en.md
docs/_posts/2020-05-21-assertion_dl_large_en.md
docs/_posts/2020-05-23-ner_clinical_large_en.md
docs/_posts/2020-05-26-embeddings_scielo_150d_es.md
docs/_posts/2020-05-26-embeddings_scielo_300d_es.md
docs/_posts/2020-05-26-embeddings_scielo_50d_es.md
docs/_posts/2020-05-26-embeddings_scielowiki_150d_es.md
docs/_posts/2020-05-26-embeddings_scielowiki_300d_es.md
docs/_posts/2020-05-26-embeddings_scielowiki_50d_es.md
docs/_posts/2020-05-27-embeddings_sciwiki_150d_es.md
docs/_posts/2020-05-27-embeddings_sciwiki_300d_es.md
docs/_posts/2020-05-27-embeddings_sciwiki_50d_es.md
docs/_posts/2020-05-29-embeddings_healthcare_100d_en.md
docs/_posts/2020-06-02-embeddings_biovec_en.md
docs/_posts/2020-06-20-chunkresolve_snomed_findings_clinical_en.md
docs/_posts/2020-06-24-chunkresolve_rxnorm_xsmall_clinical_en.md
docs/_posts/2020-07-08-ner_diag_proc_es.md
docs/_posts/2020-07-08-ner_neoplasms_es.md
docs/_posts/2020-07-27-chunkresolve_rxnorm_cd_clinical_en.md
docs/_posts/2020-07-27-chunkresolve_rxnorm_sbd_clinical_en.md
docs/_posts/2020-07-27-chunkresolve_rxnorm_scd_clinical_en.md
docs/_posts/2020-08-04-deidentify_large_en.md
docs/_posts/2020-08-19-explain_clinical_doc_carp_en.md
docs/_posts/2020-08-19-explain_clinical_doc_cra_en.md
docs/_posts/2020-09-03-re_drug_drug_interaction_clinical_en.md
docs/_posts/2020-09-06-chunkresolve_ICD10GM_de.md
docs/_posts/2020-09-06-w2v_cc_300d_de.md
docs/_posts/2020-09-13-sentence_detector_dl_healthcare_en.md
docs/_posts/2020-09-16-chunkresolve_athena_conditions_healthcare_en.md
docs/_posts/2020-09-21-ner_chemprot_clinical_en.md
docs/_posts/2020-09-21-ner_human_phenotype_gene_clinical_en.md
docs/_posts/2020-09-21-ner_human_phenotype_go_clinical_en.md
docs/_posts/2020-09-23-assertion_dl_healthcare_en.md
docs/_posts/2020-09-24-re_clinical_en.md
docs/_posts/2020-09-28-ner_healthcare_de.md
docs/_posts/2020-09-28-re_temporal_events_clinical_en.md
docs/_posts/2020-09-28-re_temporal_events_enriched_clinical_en.md
docs/_posts/2020-09-30-classifierdl_ade_biobert.md
docs/_posts/2020-09-30-explain_clinical_doc_era_en.md
docs/_posts/2020-09-30-re_human_phenotype_gene_clinical_en.md
docs/_posts/2020-11-04-ner_anatomy_coarse_biobert_en.md
docs/_posts/2020-11-04-ner_anatomy_coarse_en.md
docs/_posts/2020-11-12-classifierdl_pico_biobert_en.md
docs/_posts/2020-11-27-sbiobert_base_cased_mli_en.md
docs/_posts/2020-11-27-sbiobertresolve_cpt_en.md
docs/_posts/2020-11-27-sbiobertresolve_icd10cm_en.md
docs/_posts/2020-11-27-sbiobertresolve_icd10pcs_en.md
docs/_posts/2020-11-27-sbiobertresolve_icdo_en.md
docs/_posts/2020-11-27-sbiobertresolve_rxnorm_en.md
docs/_posts/2020-11-27-sbiobertresolve_snomed_auxConcepts_en.md
docs/_posts/2020-11-27-sbiobertresolve_snomed_auxConcepts_int_en.md
docs/_posts/2020-11-27-sbiobertresolve_snomed_findings_en.md
docs/_posts/2020-11-27-sbiobertresolve_snomed_findings_int_en.md
docs/_posts/2020-11-27-sbluebert_base_uncased_mli_en.md
docs/_posts/2020-12-11-sbiobertresolve_rxcui_en.md
docs/_posts/2020-12-13-sbiobertresolve_icd10cm_augmented_en.md
docs/_posts/2020-12-16-classifierdl_gender_biobert_en.md
docs/_posts/2020-12-16-classifierdl_gender_sbert_en.md
docs/_posts/2021-01-18-jsl_assertion_wip_en.md
docs/_posts/2021-01-18-jsl_assertion_wip_large_en.md
docs/_posts/2021-01-18-jsl_ner_wip_clinical_en.md
docs/_posts/Ahmetemintek/2021-12-24-sbiobertresolve_loinc_cased_en.md
docs/_posts/Ahmetemintek/2022-02-26-sbiobertresolve_snomed_findings_aux_concepts_en_3_0.md
docs/_posts/Ahmetemintek/2022-03-31-drug_action_treatment_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-04-01-normalized_section_header_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-04-04-drug_action_treatment_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-04-04-normalized_section_header_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-05-11-abbreviation_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-05-27-rct_binary_classifier_biobert_en_3_0.md
docs/_posts/Ahmetemintek/2022-05-27-rct_binary_classifier_use_en_3_0.md
docs/_posts/Ahmetemintek/2022-06-07-rxnorm_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-06-24-rxnorm_umls_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-05-sbiobertresolve_umls_clinical_drugs_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-05-sbiobertresolve_umls_findings_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-06-umls_clinical_drugs_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-08-umls_clinical_findings_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-11-umls_disease_syndrome_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-11-umls_drug_substance_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-11-umls_major_concepts_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-25-umls_drug_substance_resolver_pipeline_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-25-umls_major_concepts_resolver_pipeline_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-26-umls_clinical_findings_resolver_pipeline_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-26-umls_disease_syndrome_resolver_pipeline_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-26-umls_drug_resolver_pipeline_en_3_0.md
docs/_posts/Ahmetemintek/2022-08-03-explain_clinical_doc_radiology_en_3_0.md
docs/_posts/Ahmetemintek/2022-08-23-drug_ade_mapper_en.md
docs/_posts/Ahmetemintek/2022-09-15-assertion_jsl_augmented_en.md
docs/_posts/Ahmetemintek/2022-09-29-rxnorm_normalized_mapper_en.md
docs/_posts/Ahmetemintek/2022-09-30-icd10_icd9_mapper_en.md
docs/_posts/Ahmetemintek/2022-09-30-icd10_icd9_mapping_en.md
docs/_posts/Ahmetemintek/2022-09-30-icd9_icd10_mapper_en.md
docs/_posts/Ahmetemintek/2022-09-30-icd9_mapper_en.md
docs/_posts/Ahmetemintek/2022-09-30-icd9_resolver_pipeline_en.md
docs/_posts/Ahmetemintek/2022-09-30-sbiobertresolve_icd9_en.md
docs/_posts/Ahmetemintek/2022-10-12-cvx_code_mapper_en.md
docs/_posts/Ahmetemintek/2022-10-12-cvx_name_mapper_en.md
docs/_posts/Ahmetemintek/2022-10-12-cvx_resolver_pipeline_en.md
docs/_posts/Ahmetemintek/2022-10-12-sbiobertresolve_cvx_en.md
docs/_posts/C-K-Loan/2021-03-29-recognize_entities_posology_en.md
docs/_posts/Cabir40/2022-03-01-sbiobertresolve_atc_en_2_4.md
docs/_posts/Cabir40/2022-03-01-sbiobertresolve_atc_en_3_0.md
docs/_posts/Cabir40/2022-03-03-clinical_deidentification_en_2_4.md
docs/_posts/Cabir40/2022-03-03-clinical_deidentification_en_3_0.md
docs/_posts/Cabir40/2022-03-23-assertion_dl_biobert_scope_L10R10_en_3_0.md
docs/_posts/Cabir40/2022-03-24-assertion_dl_biobert_scope_L10R10_en_2_4.md
docs/_posts/Cabir40/2022-03-31-explain_clinical_doc_radiology_en_3_0.md
docs/_posts/Cabir40/2022-04-01-explain_clinical_doc_medication_en_3_0.md
docs/_posts/Cabir40/2022-04-25-sbiobertresolve_rxnorm_action_treatment_en_2_4.md
docs/_posts/Cabir40/2022-05-10-sbiobertresolve_cpt_procedures_measurements_augmented_en_3_0.md
docs/_posts/Cabir40/2022-05-11-sbiobertresolve_icd10cm_slim_billable_hcc_en_3_0.md
docs/_posts/Cabir40/2022-05-12-sbiobertresolve_icd10cm_slim_normalized_en_3_0.md
docs/_posts/Cabir40/2022-06-22-ner_biomedical_bc2gm_pipeline_en_3_0.md
docs/_posts/Cabir40/2022-06-27-ner_clinical_trials_abstracts_pipeline_en_3_0.md
docs/_posts/Cabir40/2022-06-28-clinical_deidentification_ro_3_0.md
docs/_posts/Cabir40/2022-07-26-bert_sequence_classifier_exact_age_reddit_en_3_0.md
docs/_posts/Cabir40/2022-07-26-bert_sequence_classifier_self_reported_age_tweet_en_3_0.md
docs/_posts/Cabir40/2022-07-29-ner_living_species_300_es_3_0.md
docs/_posts/Cabir40/2022-08-12-ner_clinical_bert_ro_3_0.md
docs/_posts/Cabir40/2022-08-15-ner_deid_generic_bert_ro_3_0.md
docs/_posts/Cabir40/2022-09-14-clinical_deidentification_en.md
docs/_posts/Cabir40/2022-09-16-clinical_deidentification_glove_augmented_en.md
docs/_posts/Damla-Gurbaz/2022-03-22-bert_token_classifier_drug_development_trials_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-06-bert_sequence_classifier_binary_rct_biobert_pipeline_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-06-rct_binary_classifier_biobert_pipeline_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-06-rct_binary_classifier_use_pipeline_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-abbreviation_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-drug_brandname_ndc_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icd10cm_snomed_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icd10cm_umls_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icdo_snomed_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-mesh_umls_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-normalized_section_header_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-rxnorm_umls_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-snomed_icd10cm_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-snomed_icdo_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-icd10cm_snomed_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-icd10cm_umls_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-icdo_snomed_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-mesh_umls_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-rxnorm_action_treatment_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-rxnorm_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-rxnorm_ndc_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-rxnorm_ndc_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-rxnorm_umls_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-snomed_icd10cm_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-snomed_icdo_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-snomed_umls_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-snomed_umls_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-28-drug_action_treatment_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-07-27-bert_sequence_classifier_ade_augmented_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-07-27-bert_token_classifier_ner_ade_binary_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-07-29-bert_token_classifier_ade_tweet_binary_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-08-10-explain_clinical_doc_medication_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-09-01-medication_resolver_pipeline_en.md
docs/_posts/Damla-Gurbaz/2022-09-01-medication_resolver_transform_pipeline_en.md
docs/_posts/HashamUlHaq/2020-12-08-ner_posology_greedy_en.md
docs/_posts/HashamUlHaq/2020-12-14-ner_drugs_greedy_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_ade_biobert_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_ade_clinicalbert_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_ade_conversational_biobert_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_gender_biobert_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_gender_sbert_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_pico_biobert_en.md
docs/_posts/HashamUlHaq/2021-01-26-assertion_dl_biobert_en.md
docs/_posts/HashamUlHaq/2021-01-26-assertion_dl_en.md
docs/_posts/HashamUlHaq/2021-01-26-assertion_dl_healthcare_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_bodypart_direction_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_bodypart_problem_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_bodypart_procedure_test_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_chemprot_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_clinical_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_date_clinical_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_drug_drug_interaction_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_human_phenotype_gene_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_temporal_events_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-06-sbiobertresolve_icd10cm_augmented_billable_hcc_en.md
docs/_posts/HashamUlHaq/2021-02-19-t5_base_mediqa_mnli_en.md
docs/_posts/HashamUlHaq/2021-02-24-re_test_result_date_en.md
docs/_posts/HashamUlHaq/2021-03-01-ner_events_admission_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-16-sentence_detector_dl_healthcare_en.md
docs/_posts/HashamUlHaq/2021-03-31-jsl_ner_wip_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-jsl_ner_wip_greedy_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_anatomy_coarse_biobert_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_anatomy_coarse_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_anatomy_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_aspect_based_sentiment_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_bionlp_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_cancer_genetics_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_cellular_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_chemprot_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_clinical_large_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_deid_augmented_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_deid_enriched_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_deid_large_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_deid_synthetic_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_deidentify_dl_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_diag_proc_es.md
docs/_posts/HashamUlHaq/2021-03-31-ner_diseases_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_drugs_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_drugs_greedy_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_drugs_large_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_events_admission_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_events_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_healthcare_de.md
docs/_posts/HashamUlHaq/2021-03-31-ner_human_phenotype_gene_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_human_phenotype_go_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_jsl_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_jsl_enriched_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_neoplasms_es.md
docs/_posts/HashamUlHaq/2021-03-31-ner_posology_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_posology_greedy_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_posology_large_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_posology_small_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_radiology_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_risk_factors_en.md
docs/_posts/HashamUlHaq/2021-04-01-explain_clinical_doc_ade_en.md
docs/_posts/HashamUlHaq/2021-04-01-explain_clinical_doc_carp_en.md
docs/_posts/HashamUlHaq/2021-04-01-explain_clinical_doc_era_en.md
docs/_posts/HashamUlHaq/2021-04-01-jsl_ner_wip_modifier_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-01-jsl_rd_ner_wip_greedy_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_ade_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_ade_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_ade_clinicalbert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_ade_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_anatomy_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_bacterial_species_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_bionlp_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_cellular_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_chemicals_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_chemprot_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_clinical_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_deid_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_deid_enriched_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_deid_sd_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_deid_sd_large_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_diseases_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_diseases_large_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_events_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_events_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_financial_contract_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_healthcare_slim_de.md
docs/_posts/HashamUlHaq/2021-04-01-ner_human_phenotype_gene_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_human_phenotype_go_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_jsl_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_jsl_enriched_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_measurements_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_medmentions_coarse_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_posology_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_posology_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_posology_large_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_radiology_wip_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_risk_factors_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_traffic_de.md
docs/_posts/HashamUlHaq/2021-04-01-nerdl_tumour_demo_en.md
docs/_posts/HashamUlHaq/2021-04-01-recognize_entities_posology_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_cpt_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_diseases_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_hcc_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_injuries_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_musculoskeletal_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_neoplasms_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10pcs_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icdo_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_loinc_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_ICD10GM_2021_de.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_cd_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_in_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_in_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_sbd_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_scd_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_scdc_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_scdc_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_xsmall_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_snomed_findings_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-19-re_test_problem_finding_en.md
docs/_posts/HashamUlHaq/2021-04-21-ner_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-29-sbiobertresolve_loinc_en.md
docs/_posts/HashamUlHaq/2021-04-29-sbluebertresolve_loinc_en.md
docs/_posts/HashamUlHaq/2021-04-30-sbiobertresolve_umls_findings_en.md
docs/_posts/HashamUlHaq/2021-05-02-sbiobertresolve_umls_major_concepts_en.md
docs/_posts/HashamUlHaq/2021-05-05-sbiobertresolve_HPO_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_medium_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_medium_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_mini_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_mini_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_tiny_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_tiny_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbiobert_jsl_cased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbiobert_jsl_umls_cased_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_HPO_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_cpt_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_icd10cm_augmented_billable_hcc_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_icd10cm_augmented_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_icd10cm_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_icd10pcs_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_icdo_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_loinc_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_rxcui_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_rxnorm_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_snomed_auxConcepts_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_snomed_auxConcepts_int_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_snomed_findings_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_snomed_findings_int_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_umls_findings_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_umls_major_concepts_en.md
docs/_posts/HashamUlHaq/2021-05-17-sbiobertresolve_icd10cm_slim_normalized_en.md
docs/_posts/HashamUlHaq/2021-05-21-sbertresolve_icd10cm_slim_billable_hcc_med_en.md
docs/_posts/HashamUlHaq/2021-05-21-sbiobertresolve_icd10cm_slim_billable_hcc_en.md
docs/_posts/HashamUlHaq/2021-05-30-sbiobertresolve_cpt_augmented_en.md
docs/_posts/HashamUlHaq/2021-05-30-sbiobertresolve_cpt_procedures_augmented_en.md
docs/_posts/HashamUlHaq/2021-05-30-sbiobertresolve_hcc_augmented_en.md
docs/_posts/HashamUlHaq/2021-06-30-ner_deid_generic_augmented_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_medium_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_medium_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_mini_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_mini_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_tiny_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_tiny_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbiobert_jsl_cased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbiobert_jsl_umls_cased_en.md
docs/_posts/HashamUlHaq/2021-07-01-icd10cm_umls_mapping_en.md
docs/_posts/HashamUlHaq/2021-07-01-mesh_umls_mapping_en.md
docs/_posts/HashamUlHaq/2021-07-01-rxnorm_mesh_mapping_en.md
docs/_posts/HashamUlHaq/2021-07-01-rxnorm_umls_mapping_en.md
docs/_posts/HashamUlHaq/2021-07-01-snomed_umls_mapping_en.md
docs/_posts/HashamUlHaq/2021-07-02-sbiobertresolve_cpt_procedures_measurements_augmented_en.md
docs/_posts/HashamUlHaq/2021-07-02-sbiobertresolve_icdo_base_en.md
docs/_posts/HashamUlHaq/2021-07-12-re_ade_clinical_en.md
docs/_posts/HashamUlHaq/2021-07-12-redl_ade_biobert_en.md
docs/_posts/HashamUlHaq/2021-07-15-explain_clinical_doc_ade_en.md
docs/_posts/HashamUlHaq/2021-07-16-re_ade_biobert_en.md
docs/_posts/HashamUlHaq/2021-07-26-jsl_ner_wip_greedy_biobert_en.md
docs/_posts/HashamUlHaq/2021-07-26-jsl_rd_ner_wip_greedy_biobert_en.md
docs/_posts/HashamUlHaq/2021-08-11-sentence_detector_dl_healthcare_en.md
docs/_posts/HashamUlHaq/2021-08-13-ner_jsl_slim_en.md
docs/_posts/HashamUlHaq/2021-09-01-ner_posology_experimental_en.md
docs/_posts/HashamUlHaq/2021-09-05-ner_jsl_biobert_en.md
docs/_posts/HashamUlHaq/2021-09-29-sbiobertresolve_icd10cm_generalised_en.md
docs/_posts/HashamUlHaq/2021-09-30-ner_chexpert_en.md
docs/_posts/HashamUlHaq/2021-10-03-sbiobertresolve_umls_findings_en.md
docs/_posts/HashamUlHaq/2021-10-03-sbiobertresolve_umls_major_concepts_en.md
docs/_posts/HashamUlHaq/2021-10-11-sbiobertresolve_umls_clinical_drugs_en.md
docs/_posts/HashamUlHaq/2021-10-11-sbiobertresolve_umls_disease_syndrome_en.md
docs/_posts/HashamUlHaq/2021-10-22-ner_jsl_enriched_en.md
docs/_posts/HashamUlHaq/2021-11-05-ner_covid_trials_en.md
docs/_posts/HashamUlHaq/2021-11-11-sbiobertresolve_snomed_procedures_measurements_en.md
docs/_posts/HashamUlHaq/2021-11-15-ner_nihss_en.md
docs/_posts/HashamUlHaq/2021-11-15-sbiobertresolve_clinical_snomed_procedures_measurements_en.md
docs/_posts/HashamUlHaq/2021-11-16-redl_nihss_biobert_en.md
docs/_posts/HashamUlHaq/2021-11-26-ner_biomarker_en.md
docs/_posts/HashamUlHaq/2021-12-06-sbiobertresolve_umls_drug_substance_en.md
docs/_posts/HashamUlHaq/2021-12-17-bert_token_classifier_drug_development_trials_en.md
docs/_posts/HashamUlHaq/2022-02-01-ner_supplement_clinical_en.md
docs/_posts/HashamUlHaq/2022-02-01-sbiobertresolve_clinical_abbreviation_acronym_en.md
docs/_posts/HashamUlHaq/2022-02-08-ner_nature_nero_clinical_en.md
docs/_posts/HashamUlHaq/2022-06-18-bert_token_classifier_drug_development_trials_en_3_0.md
docs/_posts/HashamUlHaq/2022-07-27-re_ade_conversational_en_3_0.md
docs/_posts/Meryem1425/2022-03-04-clinical_deidentification_glove_en_3_0.md
docs/_posts/Meryem1425/2022-03-21-bert_token_classifier_ner_jsl_en_2_4.md
docs/_posts/Meryem1425/2022-06-06-sbiobertresolve_icdo_augmented_en_3_0.md
docs/_posts/Meryem1425/2022-07-28-bert_sequence_classifier_drug_reviews_webmd_en_3_0.md
docs/_posts/Meryem1425/2022-08-04-bert_sequence_classifier_treatment_changes_sentiment_tweet_en_3_0.md
docs/_posts/albertoandreottiATgmail/2021-03-30-spellcheck_clinical_en.md
docs/_posts/albertoandreottiATgmail/2021-09-10-redl_bodypart_procedure_test_biobert_en.md
docs/_posts/alierenak/2022-07-28-classifierdl_vaccine_sentiment_en_3_0.md
docs/_posts/alierenak/2022-08-01-bert_sequence_classifier_covid_sentiment_en_3_0.md
docs/_posts/alierenak/2022-08-09-bert_sequence_classifier_depression_en_3_0.md
docs/_posts/alierenak/2022-08-09-bert_sequence_classifier_depression_twitter_en_3_0.md
docs/_posts/alierenak/2022-08-10-bert_sequence_classifier_depression_binary_en_3_0.md
docs/_posts/alierenak/2022-08-10-bert_sequence_classifier_health_mentions_bert_de_3_0.md
docs/_posts/alierenak/2022-08-10-bert_sequence_classifier_health_mentions_gbert_de_3_0.md
docs/_posts/alierenak/2022-08-10-bert_sequence_classifier_health_mentions_gbert_large_de_3_0.md
docs/_posts/alierenak/2022-08-10-bert_sequence_classifier_health_mentions_medbert_de_3_0.md
docs/_posts/aydinmyilmaz/2021-01-18-ner_radiology_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_directions_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_problem_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_proceduretest_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_date_clinical_en.md
docs/_posts/aydinmyilmaz/2021-01-20-ner_deid_augmented_en.md
docs/_posts/aydinmyilmaz/2021-01-28-deidentify_dl_en.md
docs/_posts/bunyamin-polat/2022-03-22-bert_token_classifier_drug_development_trials_en_2_4.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_bert_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_bert_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_biobert_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_roberta_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_roberta_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_fr_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_ro_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_ca_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_fr_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_gl_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-26-bert_token_classifier_ner_living_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-30-clinical_deidentification_glove_augmented_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-30-explain_clinical_doc_ade_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_anatem_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc2gm_gene_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc4chemd_chemicals_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc5cdr_chemicals_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc5cdr_disease_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_jnlpba_cellular_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_linnaeus_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_ncbi_disease_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_de.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_en.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_fr.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_it.md
docs/_posts/bunyamin-polat/2022-10-25-legner_indian_court_judgement_en.md
docs/_posts/bunyamin-polat/2022-10-25-legner_indian_court_preamble_en.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_de.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_en.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_fr.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_it.md
docs/_posts/dcecchini/2021-01-29-ner_drugs_large_en.md
docs/_posts/dcecchini/2021-07-23-cantemist_scielowiki_es.md
docs/_posts/dcecchini/2021-07-26-meddroprof_scielowiki_es.md
docs/_posts/egenc/2022-01-03-bert_token_classifier_ner_bionlp_en.md
docs/_posts/egenc/2022-01-04-bert_token_classifier_ner_ade_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_anatomy_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_cellular_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_chemicals_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_chemprot_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_clinical_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_deid_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_drugs_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_jsl_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_jsl_slim_en.md
docs/_posts/egenc/2022-01-07-bert_token_classifier_ner_bacteria_en.md
docs/_posts/egenc/2022-01-17-sbertresolve_ner_model_finder_en.md
docs/_posts/egenc/2022-01-18-ner_profiling_biobert_en.md
docs/_posts/egenc/2022-01-18-ner_profiling_clinical_en.md
docs/_posts/egenc/2022-01-18-sbiobertresolve_icd10cm_augmented_en.md
docs/_posts/egenc/2022-01-18-sbiobertresolve_loinc_augmented_en.md
docs/_posts/egenc/2022-01-18-sbiobertresolve_mesh_en.md
docs/_posts/egenc/2022-01-18-sbiobertresolve_snomed_drug_en.md
docs/_posts/egenc/2022-01-18-sbluebertresolve_loinc_uncased_en.md
docs/_posts/egenc/2022-01-21-ner_model_finder_en.md
docs/_posts/egenc/2022-01-21-ner_profiling_biobert_en.md
docs/_posts/egenc/2022-01-21-sbiobertresolve_icd10cm_augmented_en.md
docs/_posts/egenc/2022-02-28-sbiobertresolve_hcpcs_en_2_4.md
docs/_posts/egenc/2022-02-28-sbiobertresolve_hcpcs_en_3_0.md
docs/_posts/gadde5300/2022-02-09-bert_token_classifier_ner_supplement_en.md
docs/_posts/gadde5300/2022-03-01-bert_sequence_classifier_rct_biobert_en_2_4.md
docs/_posts/gadde5300/2022-03-01-bert_sequence_classifier_rct_biobert_en_3_0.md
docs/_posts/gadde5300/2022-03-17-assertion_dl_scope_L10R10_en_2_4.md
docs/_posts/gadde5300/2022-03-17-assertion_dl_scope_L10R10_en_3_0.md
docs/_posts/gadde5300/2022-04-25-bert_sequence_classifier_binary_rct_biobert_en_3_0.md
docs/_posts/gadde5300/2022-10-17-legner_confidentiality_en.md
docs/_posts/gadde5300/2022-10-17-legner_warranty_en.md
docs/_posts/gadde5300/2022-10-18-legre_confidentiality_en.md
docs/_posts/gadde5300/2022-10-19-legre_warranty_en.md
docs/_posts/galiph/2021-12-21-jsl_sbert_medium_rxnorm_en.md
docs/_posts/galiph/2021-12-23-sbert_jsl_medium_rxnorm_uncased_en.md
docs/_posts/galiph/2021-12-23-sbiobert_jsl_rxnorm_cased_en.md
docs/_posts/galiph/2021-12-27-sbiobertresolve_jsl_rxnorm_augmented_en.md
docs/_posts/galiph/2021-12-28-sbertresolve_jsl_rxnorm_augmented_med_en.md
docs/_posts/galiph/2021-12-28-sbiobertresolve_rxnorm_augmented_cased_en.md
docs/_posts/galiph/2021-12-28-sbluebertresolve_rxnorm_augmented_uncased_en.md
docs/_posts/galiph/2022-01-03-sbert_jsl_medium_rxnorm_uncased_en.md
docs/_posts/galiph/2022-01-03-sbiobertresolve_rxnorm_augmented_en.md
docs/_posts/galiph/2022-01-06-clinical_deidentification_de.md
docs/_posts/galiph/2022-01-06-ner_deid_generic_de.md
docs/_posts/galiph/2022-01-06-ner_deid_subentity_de.md
docs/_posts/galiph/2022-01-08-clinical_deidentification_de.md
docs/_posts/galiph/2022-02-09-sbiobertresolve_rxnorm_augmented_re_en.md
docs/_posts/galiph/2022-03-03-clinical_deidentification_de_3_0.md
docs/_posts/galiph/2022-03-03-german_deid_pipeline_spark24_de_2_4.md
docs/_posts/galiph/2022-04-18-sbiobertresolve_ndc_en_2_4.md
docs/_posts/galiph/2022-05-08-rxnorm_action_treatment_mapper_en_3_0.md
docs/_posts/galiph/2022-05-09-rxnorm_ndc_mapper_en_3_0.md
docs/_posts/galiph/2022-05-11-drug_brandname_ndc_mapper_en_3_0.md
docs/_posts/galiph/2022-05-20-rxnorm_ndc_mapper_en_3_0.md
docs/_posts/galiph/2022-07-28-ner_medication_pipeline_en_3_0.md
docs/_posts/galiph/2022-08-01-medication_resolver_pipeline_en_3_0.md
docs/_posts/galiph/2022-08-01-medication_resolver_transform_pipeline_en_3_0.md
docs/_posts/gokhanturer/2022-07-26-ner_living_species_300_es_3_0.md
docs/_posts/gokhanturer/2022-07-28-bert_sequence_classifier_self_reported_partner_violence_tweet_en_3_0.md
docs/_posts/gokhanturer/2022-07-29-bert_sequence_classifier_self_reported_vaccine_status_tweet_en_3_0.md
docs/_posts/gokhanturer/2022-10-15-finre_has_ticker_en.md
docs/_posts/gpirge/2022-06-28-ner_pathogen_en_3_0.md
docs/_posts/gpirge/2022-06-29-ner_pathogen_pipeline_en_3_0.md
docs/_posts/gpirge/2022-07-28-bert_sequence_classifier_self_reported_symptoms_tweet_es_3_0.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_disease_mentions_tweet_es_3_0.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_ner_pathogen_en_3_0.md
docs/_posts/gpirge/2022-08-08-bert_sequence_classifier_health_mandates_premise_tweet_en_3_0.md
docs/_posts/gpirge/2022-08-08-bert_sequence_classifier_health_mandates_stance_tweet_en_3_0.md
docs/_posts/gpirge/2022-08-11-bert_token_classifier_negation_uncertainty_es_3_0.md
docs/_posts/gpirge/2022-08-11-bert_token_classifier_ner_clinical_trials_abstracts_es_3_0.md
docs/_posts/gpirge/2022-08-11-bert_token_classifier_pharmacology_es_3_0.md
docs/_posts/gpirge/2022-08-12-ner_clinical_trials_abstracts_es_3_0.md
docs/_posts/gpirge/2022-08-13-ner_negation_uncertainty_es_3_0.md
docs/_posts/gpirge/2022-08-13-ner_pharmacology_es_3_0.md
docs/_posts/gpirge/2022-08-14-disease_mentions_tweet_es_3_0.md
docs/_posts/hsaglamlar/2022-06-30-ner_clinical_bert_ro_3_0.md
docs/_posts/hsaglamlar/2022-07-01-ner_clinical_ro_3_0.md
docs/_posts/hsaglamlar/2022-07-29-bert_sequence_classifier_self_reported_stress_tweet_en_3_0.md
docs/_posts/iamvarol/2021-11-23-sbiobertresolve_loinc_augmented_en.md
docs/_posts/iamvarol/2021-12-31-sbluebertresolve_loinc_uncased_en.md
docs/_posts/josejuanmartinez/2021-11-03-robertaresolve_snomed_es.md
docs/_posts/josejuanmartinez/2021-11-04-roberta_ner_diag_proc_es.md
docs/_posts/josejuanmartinez/2021-11-05-bert_sequence_classifier_question_statement_clinical_en.md
docs/_posts/josejuanmartinez/2022-01-17-ner_deid_generic_roberta_es.md
docs/_posts/josejuanmartinez/2022-01-17-ner_deid_subentity_roberta_es.md
docs/_posts/josejuanmartinez/2022-01-18-ner_deid_generic_es.md
docs/_posts/josejuanmartinez/2022-01-18-ner_deid_subentity_es.md
docs/_posts/josejuanmartinez/2022-01-24-clinical_deidentification_es.md
docs/_posts/josejuanmartinez/2022-02-11-clinical_deidentification_es.md
docs/_posts/josejuanmartinez/2022-02-14-clinical_deidentification_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_generic_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_generic_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_subentity_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_subentity_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-clinical_deidentification_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_generic_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_generic_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_subentity_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_subentity_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-17-clinical_deidentification_es.md
docs/_posts/josejuanmartinez/2022-03-02-clinical_deidentification_es_2_4.md
docs/_posts/josejuanmartinez/2022-03-03-clinical_deidentification_augmented_es_2_4.md
docs/_posts/josejuanmartinez/2022-03-22-clinical_deidentification_glove_augmented_en_3_0.md
docs/_posts/josejuanmartinez/2022-04-05-re_zeroshot_biobert_en_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_generic_pt_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_subentity_pt_3_0.md
docs/_posts/josejuanmartinez/2022-04-14-clinical_deidentification_pt_3_0.md
docs/_posts/josejuanmartinez/2022-06-21-clinical_deidentification_pt_3_0.md
docs/_posts/josejuanmartinez/2022-08-09-finclf_bank_complaints_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finclf_distilroberta_sentiment_analysis_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finel_crunchbase_companynames_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finmapper_crunchbase_companyname_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finmapper_nasdaq_companyname_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finmapper_nasdaq_ticker_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finner_deid_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finner_roberta_ticker_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finner_ticker_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finqa_roberta_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legclf_conventions_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legclf_human_rights_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legel_crunchbase_companynames_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legmapper_crunchbase_companyname_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legner_cuad_silver_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legner_deid_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legqa_bert_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legqa_bert_large_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legqa_roberta_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_business_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_controls_procedures_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_equity_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_executives_compensation_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_executives_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_exhibits_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_financial_conditions_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_financial_statements_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_form_10k_summary_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_legal_proceedings_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_market_risk_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_properties_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_risk_factors_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_security_ownership_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_absence_of_certain_changes_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_acceleration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_access_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_accounting_terms_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_adjustments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_agreements_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_amendments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_application_of_proceeds_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_appointment_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_approvals_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_arbitration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_assignments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_authority_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_authorization_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_auto_renewal_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_background_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_bank_accounts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_bankruptcy_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_base_salary_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_benefits_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_bereavement_leave_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_binding_effect_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_bonus_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_books_and_records_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_brokers_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_cancellation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_capitalization_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_captions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_cause_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_certain_definitions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_certificates_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_change_in_control_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_change_of_control_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_closing_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_collateral_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_compensation_and_benefits_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_compensation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_compliance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_compliance_with_laws_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_condemnation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_conditions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_conditions_to_effectiveness_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_conduct_of_business_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_confidential_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_conflict_of_interest_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_consents_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_consideration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_construction_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_contracts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_contribution_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_cooperation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_corporate_existence_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_costs_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_counterparts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_covenants_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_currency_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_death_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_defaults_and_remedies_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_defaults_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_definitions_and_interpretation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_definitions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_delegation_of_duties_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_delivery_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_disability_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_disclaimer_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_disclosure_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_dispute_resolution_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_disputes_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_dissolution_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_distributions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_dividends_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_documents_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_duration_and_termination_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_duration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_duties_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_effective_date_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_effectiveness_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_employees_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_employment_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_erisa_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_exceptions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_exclusions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_exclusivity_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_execution_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_execution_in_counterparts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_exercise_of_option_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_exhibits_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_expenses_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_fees_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_financial_information_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_financial_statements_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_fiscal_year_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_force_majeure_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_fractional_shares_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_full_disclosure_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_further_assurances_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_general_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_good_reason_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_grant_of_option_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_grant_of_security_interest_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_guarantee_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_headings_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_holidays_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_illegality_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_in_witness_whereof_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_increased_costs_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_indebtedness_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_indemnification_by_the_company_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_indemnification_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_indemnity_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_independent_contractor_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_information_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_injunctive_relief_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_insolvency_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_inspection_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_insurance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_integration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_intellectual_property_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_interest_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_interpretation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_introduction_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_investment_company_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_investments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_judgments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_jurisdiction_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_labor_matters_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_laws_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_legal_proceedings_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_legends_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_letters_of_credit_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_liabilities_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_liability_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_licenses_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_liens_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_limitations_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_listing_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_litigation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_loans_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_maintenance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_management_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_marketing_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_material_contracts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_meetings_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_merger_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_miscellaneous_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_modification_and_waiver_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_modifications_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_name_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_negative_covenants_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_assignment_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_conflicts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_default_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_material_adverse_change_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_solicitation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_strict_construction_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_third_party_beneficiaries_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_violation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_waiver_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_non_competition_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_non_discrimination_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_non_disparagement_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_non_solicitation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_notices_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_notification_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_now_therefore_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_obligations_absolute_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_officers_certificate_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_officers_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_optional_renewal_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_organization_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_other_benefits_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_other_remedies_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_ownership_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_parking_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_partial_invalidity_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_participations_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_parties_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_parties_in_interest_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_payments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_performance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_permits_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_persons_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_position_and_duties_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_powers_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_preamble_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_procedures_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_proprietary_rights_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_provisions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_public_announcements_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_publicity_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_purchase_and_sale_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_purchase_price_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_purpose_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_real_property_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_recitals_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_recognition_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_records_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_redemption_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_registration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_registration_expenses_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_registration_rights_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_reimbursements_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_reinstatement_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_relationship_of_the_parties_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_release_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_reliance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_remedies_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_remedies_cumulative_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_rent_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_reporting_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_reports_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_representations_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_resignation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_restrictions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_restrictions_on_transfer_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_right_of_setoff_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_rules_of_construction_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_salary_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_scope_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_section_headings_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_security_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_security_interest_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_seniority_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_services_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_set_off_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_severability_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_severance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_sick_leave_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_solvency_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_special_terms_and_conditions_of_trust_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_specific_performance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_standard_of_care_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_standard_terms_and_conditions_of_trust_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_stock_options_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_subordination_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_subrogation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_subsidiaries_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_successors_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_support_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_tax_returns_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_tax_withholding_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_taxes_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_term_and_termination_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_term_of_employment_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_termination_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_termination_of_agreement_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_termination_of_employment_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_terms_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_the_closing_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_the_merger_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_therefore_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_third_party_beneficiaries_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_time_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_title_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_transactions_with_affiliates_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_transfer_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_transfers_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_trustee_may_file_proofs_of_claim_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_undertaking_for_costs_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_usa_patriot_act_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_use_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_use_of_proceeds_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_utilities_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_vacation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_validity_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_vesting_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_voting_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_waiver_of_jury_trial_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_waivers_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_warranty_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_whereas_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_witnesseth_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-12-legner_bert_grants_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-12-legner_headers_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-12-legner_whereas_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-12-legre_contract_doc_parties_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-16-finner_arabert_arabic_ar_3_2.md
docs/_posts/josejuanmartinez/2022-08-16-legner_contract_doc_parties_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-16-legner_signers_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-finassertion_competitors_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-finner_10k_summary_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-finner_orgs_prods_alias_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-finre_org_prod_alias_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-legner_orgs_prods_alias_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-legre_org_prod_alias_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-18-finmapper_edgar_companyname_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-18-finmapper_edgar_irs_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-18-legmapper_edgar_companyname_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-18-legmapper_edgar_irs_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-22-finre_zero_shot_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-22-legner_obligations_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-22-legre_zero_shot_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-24-legpipe_obligations_en.md
docs/_posts/josejuanmartinez/2022-08-24-legpipe_whereas_en.md
docs/_posts/josejuanmartinez/2022-08-24-legre_whereas_en.md
docs/_posts/josejuanmartinez/2022-08-29-finner_headers_en.md
docs/_posts/josejuanmartinez/2022-08-30-finel_edgar_company_name_en.md
docs/_posts/josejuanmartinez/2022-08-30-finel_edgar_irs_en.md
docs/_posts/josejuanmartinez/2022-08-30-finmulticlf_news_en.md
docs/_posts/josejuanmartinez/2022-08-30-finner_bert_roles_en.md
docs/_posts/josejuanmartinez/2022-08-30-finner_org_per_role_date_en.md
docs/_posts/josejuanmartinez/2022-08-30-legel_edgar_company_name_en.md
docs/_posts/josejuanmartinez/2022-08-30-legel_edgar_irs_en.md
docs/_posts/josejuanmartinez/2022-08-30-legmulticlf_edgar_en.md
docs/_posts/josejuanmartinez/2022-08-31-finner_sec_conll_en.md
docs/_posts/josejuanmartinez/2022-08-31-finpipe_deid_en.md
docs/_posts/josejuanmartinez/2022-08-31-legpipe_deid_en.md
docs/_posts/josejuanmartinez/2022-09-02-finner_roberta_zeroshot_en.md
docs/_posts/josejuanmartinez/2022-09-02-legner_roberta_zeroshot_en.md
docs/_posts/josejuanmartinez/2022-09-06-finclf_augmented_esg_en.md
docs/_posts/josejuanmartinez/2022-09-06-finclf_bert_fls_en.md
docs/_posts/josejuanmartinez/2022-09-06-finclf_bert_sentiment_en.md
docs/_posts/josejuanmartinez/2022-09-06-finclf_esg_en.md
docs/_posts/josejuanmartinez/2022-09-07-finclf_bert_sentiment_phrasebank_en.md
docs/_posts/josejuanmartinez/2022-09-07-finvisualclf_vit_tickets_en.md
docs/_posts/josejuanmartinez/2022-09-07-legclf_bert_judgements_agent_en.md
docs/_posts/josejuanmartinez/2022-09-07-legclf_bert_judgements_argtype_en.md
docs/_posts/josejuanmartinez/2022-09-08-finel_names2tickers_en.md
docs/_posts/josejuanmartinez/2022-09-08-finre_acquisitions_subsidiaries_en.md
docs/_posts/josejuanmartinez/2022-09-09-finassertiondl_past_roles_en.md
docs/_posts/josejuanmartinez/2022-09-09-finel_tickers2names_en.md
docs/_posts/josejuanmartinez/2022-09-09-finpipe_org_per_role_date_en.md
docs/_posts/josejuanmartinez/2022-09-20-legclf_cuad_confidentiality_clause_en.md
docs/_posts/josejuanmartinez/2022-09-20-legclf_cuad_obligations_clause_en.md
docs/_posts/josejuanmartinez/2022-09-20-legclf_cuad_whereas_clause_en.md
docs/_posts/josejuanmartinez/2022-09-21-visualner_10kfilings_en.md
docs/_posts/josejuanmartinez/2022-09-21-visualner_keyvalue_10kfilings_en.md
docs/_posts/josejuanmartinez/2022-09-21-visualner_receipts_xx.md
docs/_posts/josejuanmartinez/2022-09-27-finassertion_time_en.md
docs/_posts/josejuanmartinez/2022-09-27-finner_bert_rufacts_ru.md
docs/_posts/josejuanmartinez/2022-09-27-legassertion_time_en.md
docs/_posts/josejuanmartinez/2022-09-27-legclf_cuad_indemnifications_clause_en.md
docs/_posts/josejuanmartinez/2022-09-27-legclf_cuad_licenses_clause_en.md
docs/_posts/josejuanmartinez/2022-09-27-legner_bert_indemnifications_en.md
docs/_posts/josejuanmartinez/2022-09-27-legner_br_base_pt.md
docs/_posts/josejuanmartinez/2022-09-27-legner_br_large_pt.md
docs/_posts/josejuanmartinez/2022-09-28-finclf_bert_banking77_en.md
docs/_posts/josejuanmartinez/2022-09-28-finre_work_experience_en.md
docs/_posts/josejuanmartinez/2022-09-28-legclf_enforceability_clause_en.md
docs/_posts/josejuanmartinez/2022-09-28-legclf_enforcement_clause_en.md
docs/_posts/josejuanmartinez/2022-09-28-legclf_environmental_matters_clause_en.md
docs/_posts/josejuanmartinez/2022-09-28-legner_br_bert_base_pt.md
docs/_posts/josejuanmartinez/2022-09-28-legner_br_bert_large_pt.md
docs/_posts/josejuanmartinez/2022-09-28-legner_law_money_es.md
docs/_posts/josejuanmartinez/2022-09-28-legner_laws_treaties_es.md
docs/_posts/josejuanmartinez/2022-09-28-legre_indemnifications_en.md
docs/_posts/josejuanmartinez/2022-10-02-legner_arabert_arabic_ar.md
docs/_posts/josejuanmartinez/2022-10-02-legner_bert_base_courts_de.md
docs/_posts/josejuanmartinez/2022-10-02-legner_bert_large_courts_de.md
docs/_posts/josejuanmartinez/2022-10-02-legner_courts_de.md
docs/_posts/josejuanmartinez/2022-10-18-legclf_cuad_warranty_clause_en.md
docs/_posts/josejuanmartinez/2022-10-19-finner_financial_medium_en.md
docs/_posts/josejuanmartinez/2022-10-19-finner_financial_small_en.md
docs/_posts/josejuanmartinez/2022-10-20-finner_financial_large_en.md
docs/_posts/josejuanmartinez/2022-10-22-finclf_bert_sentiment_analysis_lt.md
docs/_posts/josejuanmartinez/2022-10-22-finel_nasdaq_data_company_name_en.md
docs/_posts/josejuanmartinez/2022-10-22-finel_nasdaq_data_ticker_en.md
docs/_posts/josejuanmartinez/2022-10-22-finmapper_nasdaq_data_company_name_en.md
docs/_posts/josejuanmartinez/2022-10-22-finmapper_nasdaq_data_ticker_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_consulting_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_credit_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_employment_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_lease_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_loan_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_management_contract_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_purchase_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_service_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-25-finner_sec_10k_summary_en.md
docs/_posts/kolia1985/2021-12-09-text_detection_v1_en.md
docs/_posts/kolia1985/2021-12-14-text_detection_v1_en.md
docs/_posts/kolia1985/2021-12-21-text_cleaner_v1_en.md
docs/_posts/kolia1985/2022-02-16-ocr_base_handwritten_en.md
docs/_posts/kolia1985/2022-02-16-ocr_small_printed_en.md
docs/_posts/kolia1985/2022-02-17-ocr_small_handwritten_en.md
docs/_posts/kolia1985/2022-06-15-ocr_base_handwritten_v2_en_3_0.md
docs/_posts/kolia1985/2022-07-16-layoutlmv3_finetuned_funsd_en_3_2.md
docs/_posts/luca-martial/2021-12-20-ner_drugprot_clinical_en.md
docs/_posts/luca-martial/2022-01-05-re_drugprot_clinical_en.md
docs/_posts/luca-martial/2022-01-05-redl_drugprot_biobert_en.md
docs/_posts/luca-martial/2022-02-07-bert_sequence_classifier_pico_biobert_en.md
docs/_posts/luca-martial/2022-02-08-bert_sequence_classifier_ade_en.md
docs/_posts/luca-martial/2022-02-08-bert_sequence_classifier_gender_biobert_en.md
docs/_posts/luca-martial/2022-02-08-distilbert_sequence_classifier_ade_en.md
docs/_posts/luca-martial/2022-02-11-ner_deid_generic_fr.md
docs/_posts/luca-martial/2022-02-11-ner_deid_subentity_fr.md
docs/_posts/luca-martial/2022-02-14-ner_deid_subentity_fr.md
docs/_posts/luca-martial/2022-02-23-clinical_deidentification_fr.md
docs/_posts/luca-martial/2022-03-04-clinical_deidentification_fr_2_4.md
docs/_posts/luca-martial/2022-03-22-ner_deid_subentity_it_3_0.md
docs/_posts/luca-martial/2022-03-25-ner_deid_generic_it_2_4.md
docs/_posts/luca-martial/2022-03-25-ner_deid_generic_it_3_0.md
docs/_posts/luca-martial/2022-03-25-ner_deid_subentity_it_2_4.md
docs/_posts/luca-martial/2022-03-28-clinical_deidentification_it_2_4.md
docs/_posts/luca-martial/2022-03-28-clinical_deidentification_it_3_0.md
docs/_posts/luca-martial/2022-06-22-ner_clinical_trials_abstracts_en_3_0.md
docs/_posts/luca-martial/2022-06-29-bert_token_classifier_ner_clinical_trials_abstracts_en_3_0.md
docs/_posts/luca-martial/2022-07-08-clinical_deidentification_wip_en_3_0.md
docs/_posts/luca-martial/2022-07-24-clinical_deidentification_en_3_0.md
docs/_posts/luca-martial/2022-07-24-clinical_deidentification_slim_en_3_0.md
docs/_posts/mauro-nievoff/2022-07-25-assertion_oncology_treatment_binary_wip_en_3_0.md
docs/_posts/mauro-nievoff/2022-07-25-ner_oncology_wip_en_3_0.md
docs/_posts/mauro-nievoff/2022-09-26-re_oncology_size_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_biomarker_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_granular_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_location_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_temporal_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_test_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-09-28-redl_oncology_size_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biomarker_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_granular_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_location_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_temporal_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_test_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_anatomy_general_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_demographics_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_diagnosis_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_test_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_therapy_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_tnm_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_unspecific_posology_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_test_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_anatomy_granular_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_biomarker_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_posology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_wip_en.md
docs/_posts/muhammetsnts/2021-04-30-ner_jsl_en.md
docs/_posts/muhammetsnts/2021-05-02-snomed_icd10cm_mapping_en.md
docs/_posts/muhammetsnts/2021-05-04-icd10cm_umls_mapping_en.md
docs/_posts/muhammetsnts/2021-05-04-mesh_umls_mapping_en.md
docs/_posts/muhammetsnts/2021-05-04-rxnorm_mesh_mapping_en.md
docs/_posts/muhammetsnts/2021-05-04-rxnorm_umls_mapping_en.md
docs/_posts/muhammetsnts/2021-05-04-snomed_umls_mapping_en.md
docs/_posts/muhammetsnts/2021-05-25-sbertresolve_icd10cm_slim_billable_hcc_med_en.md
docs/_posts/muhammetsnts/2021-05-25-sbiobertresolve_icd10cm_slim_billable_hcc_en.md
docs/_posts/muhammetsnts/2021-05-27-clinical_deidentification_en.md
docs/_posts/muhammetsnts/2021-06-01-redl_bodypart_direction_biobert_en.md
docs/_posts/muhammetsnts/2021-06-01-redl_bodypart_problem_biobert_en.md
docs/_posts/muhammetsnts/2021-06-01-redl_bodypart_procedure_test_biobert_en.md
docs/_posts/muhammetsnts/2021-06-01-redl_date_clinical_biobert_en.md
docs/_posts/muhammetsnts/2021-06-08-clinical_deidentification_glove_en.md
docs/_posts/muhammetsnts/2021-06-15-sbertresolve_snomed_bodyStructure_med_en.md
docs/_posts/muhammetsnts/2021-06-15-sbiobertresolve_cpt_procedures_augmented_en.md
docs/_posts/muhammetsnts/2021-06-15-sbiobertresolve_snomed_bodyStructure_en.md
docs/_posts/muhammetsnts/2021-06-15-sbiobertresolve_snomed_findings_en.md
docs/_posts/muhammetsnts/2021-06-21-ner_jsl_en.md
docs/_posts/muhammetsnts/2021-06-21-ner_jsl_greedy_en.md
docs/_posts/muhammetsnts/2021-06-22-sbiobertresolve_icdo_augmented_en.md
docs/_posts/muhammetsnts/2021-06-24-ner_jsl_en.md
docs/_posts/muhammetsnts/2021-06-24-ner_jsl_greedy_en.md
docs/_posts/muhammetsnts/2021-06-25-ner_genetic_variants_en.md
docs/_posts/muhammetsnts/2021-07-08-sbertresolve_snomed_bodyStructure_med_en.md
docs/_posts/muhammetsnts/2021-07-08-sbiobertresolve_snomed_bodyStructure_en.md
docs/_posts/muhammetsnts/2021-07-14-sbiobertresolve_snomed_findings_aux_concepts_en.md
docs/_posts/muhammetsnts/2021-07-24-assertion_jsl_en.md
docs/_posts/muhammetsnts/2021-07-24-assertion_jsl_large_en.md
docs/_posts/muhammetsnts/2021-07-24-redl_chemprot_biobert_en.md
docs/_posts/muhammetsnts/2021-07-24-redl_clinical_biobert_en.md
docs/_posts/muhammetsnts/2021-07-24-redl_drug_drug_interaction_biobert_en.md
docs/_posts/muhammetsnts/2021-07-24-redl_human_phenotype_gene_biobert_en.md
docs/_posts/muhammetsnts/2021-07-24-redl_temporal_events_biobert_en.md
docs/_posts/muhammetsnts/2021-08-12-sbiobertresolve_rxnorm_disposition_en.md
docs/_posts/muhammetsnts/2021-08-13-ner_jsl_greedy_biobert_en.md
docs/_posts/muhammetsnts/2021-08-26-sbertresolve_icd10cm_slim_billable_hcc_med_en.md
docs/_posts/muhammetsnts/2021-08-26-sbiobertresolve_icd10cm_slim_billable_hcc_en.md
docs/_posts/muhammetsnts/2021-08-28-bert_token_classifier_ner_clinical_en.md
docs/_posts/muhammetsnts/2021-08-28-bert_token_classifier_ner_jsl_en.md
docs/_posts/muhammetsnts/2021-08-28-sbertresolve_rxnorm_disposition_en.md
docs/_posts/muhammetsnts/2021-08-28-sbertresolve_snomed_conditions_en.md
docs/_posts/muhammetsnts/2021-09-15-ner_healthcare_de.md
docs/_posts/muhammetsnts/2021-09-15-spellcheck_drug_norvig_en.md
docs/_posts/muhammetsnts/2021-09-16-sbertresolve_icd10gm_de.md
docs/_posts/muhammetsnts/2021-09-16-sbertresolve_snomed_de.md
docs/_posts/muhammetsnts/2021-09-23-ner_profiling_biobert_en.md
docs/_posts/muhammetsnts/2021-09-24-ner_profiling_clinical_en.md
docs/_posts/muhammetsnts/2021-09-29-sbiobertresolve_hcpcs_en.md
docs/_posts/muhammetsnts/2021-10-05-sbiobertresolve_rxnorm_ndc_en.md
docs/_posts/muhammetsnts/2021-10-10-sbiobertresolve_rxnorm_en.md
docs/_posts/muhammetsnts/2021-10-31-sbiobertresolve_icd10cm_augmented_en.md
docs/_posts/muhammetsnts/2021-11-01-sbiobertresolve_icd10cm_augmented_billable_hcc_en.md
docs/_posts/muhammetsnts/2021-11-03-ner_profiling_biobert_en.md
docs/_posts/muhammetsnts/2021-11-03-ner_profiling_clinical_en.md
docs/_posts/muhammetsnts/2021-11-14-sbiobertresolve_mesh_en.md
docs/_posts/muhammetsnts/2021-11-24-ner_model_finder_en.md
docs/_posts/muhammetsnts/2021-11-24-sbertresolve_ner_model_finder_en.md
docs/_posts/muhammetsnts/2021-11-27-sbiobertresolve_ndc_en.md
docs/_posts/muhammetsnts/2021-12-11-sbiobertresolve_clinical_abbreviation_acronym_en.md
docs/_posts/muhammetsnts/2021-12-22-icd10_icd9_mapping_en.md
docs/_posts/muhammetsnts/2021-12-30-ner_abbreviation_clinical_en.md
docs/_posts/muhammetsnts/2022-01-01-sbiobertresolve_snomed_drug_en.md
docs/_posts/muhammetsnts/2022-01-03-sbiobertresolve_clinical_abbreviation_acronym_en.md
docs/_posts/muhammetsnts/2022-06-28-bert_sequence_classifier_stress_en_3_0.md
docs/_posts/muhammetsnts/2022-07-25-bert_sequence_classifier_health_mentions_en_3_0.md
docs/_posts/muhammetsnts/2022-07-25-classifierdl_health_mentions_en_3_0.md
docs/_posts/muhammetsnts/2022-07-27-bert_sequence_classifier_stressor_en_3_0.md
docs/_posts/muhammetsnts/2022-07-28-bert_sequence_classifier_vaccine_sentiment_en_3_0.md
docs/_posts/muhammetsnts/2022-08-28-ner_profiling_biobert_en.md
docs/_posts/muhammetsnts/2022-08-29-zero_shot_ner_roberta_en.md
docs/_posts/muhammetsnts/2022-08-30-ner_profiling_clinical_en.md
docs/_posts/muhammetsnts/2022-09-05-ner_model_finder_en.md
docs/_posts/muhammetsnts/2022-09-05-sbertresolve_ner_model_finder_en.md
docs/_posts/murat-gunay/2020-09-01-posology_re.md
docs/_posts/murat-gunay/2021-03-18-assertion_dl_radiology_en.md
docs/_posts/murat-gunay/2021-06-01-ner_deid_generic_augmented_en.md
docs/_posts/murat-gunay/2021-06-06-ner_deid_generic_glove_en.md
docs/_posts/murat-gunay/2021-06-06-ner_deid_subentity_glove_en.md
docs/_posts/murat-gunay/2021-09-03-ner_deid_subentity_augmented_en.md
docs/_posts/murat-gunay/2021-09-13-bert_token_classifier_ner_deid_en.md
docs/_posts/murat-gunay/2021-09-16-bert_token_classifier_ner_jsl_en.md
docs/_posts/murat-gunay/2021-09-20-bert_token_classifier_ner_drugs_en.md
docs/_posts/murat-gunay/2021-09-24-bert_token_classifier_ner_jsl_slim_en.md
docs/_posts/murat-gunay/2021-09-30-bert_token_classifier_ner_ade_en.md
docs/_posts/murat-gunay/2021-09-30-bert_token_classifier_ner_anatomy_en.md
docs/_posts/murat-gunay/2021-09-30-bert_token_classifier_ner_bacteria_en.md
docs/_posts/murat-gunay/2021-10-19-bert_token_classifier_ner_chemicals_en.md
docs/_posts/murat-gunay/2021-10-19-bert_token_classifier_ner_chemprot_en.md
docs/_posts/murat-gunay/2021-11-03-bert_token_classifier_ner_bionlp_en.md
docs/_posts/murat-gunay/2021-11-03-bert_token_classifier_ner_cellular_en.md
docs/_posts/murat-gunay/2021-11-04-ner_chemd_clinical_en.md
docs/_posts/murat-gunay/2021-11-29-ner_deid_subentity_augmented_i2b2_en.md
docs/_posts/murat-gunay/2022-03-09-bert_token_classifier_ner_cellular_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-10-bert_token_classifier_ner_cellular_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-03-14-bert_token_classifier_ner_chemicals_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-03-14-bert_token_classifier_ner_chemicals_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-15-bert_token_classifier_ner_chemprot_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-03-15-bert_token_classifier_ner_chemprot_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-15-bert_token_classifier_ner_clinical_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-03-15-bert_token_classifier_ner_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_ade_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_anatomy_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_bacteria_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_bionlp_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_cellular_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_chemicals_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_chemprot_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_deid_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_drugs_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_jsl_slim_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_ner_wip_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_ner_wip_greedy_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_ner_wip_greedy_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_ner_wip_modifier_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_rd_ner_wip_greedy_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_rd_ner_wip_greedy_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_abbreviation_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_ade_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_ade_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_ade_clinicalbert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_anatomy_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_anatomy_coarse_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_anatomy_coarse_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_anatomy_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_bacterial_species_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_biomarker_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_bionlp_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_bionlp_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_cancer_genetics_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_cellular_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_cellular_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_chemicals_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_chemprot_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_chemprot_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_chexpert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_clinical_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_clinical_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_augmented_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_enriched_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_enriched_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_generic_augmented_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_generic_pipeline_de_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_sd_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_sd_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_subentity_augmented_i2b2_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_subentity_augmented_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_subentity_pipeline_de_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deidentify_dl_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_diseases_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_diseases_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_diseases_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_drugprot_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_drugs_greedy_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_drugs_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_drugs_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_events_admission_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_events_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_events_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_genetic_variants_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_human_phenotype_gene_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_human_phenotype_gene_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_human_phenotype_go_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_human_phenotype_go_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_enriched_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_enriched_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_greedy_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_greedy_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_slim_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_measurements_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_medmentions_coarse_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_nihss_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_experimental_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_greedy_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_large_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_small_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_radiology_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_radiology_wip_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_risk_factors_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_risk_factors_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_ade_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_events_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_posology_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-23-bert_token_classifier_drug_development_trials_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-23-bert_token_classifier_ner_jsl_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_bodypart_directions_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_bodypart_proceduretest_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_date_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_human_phenotype_gene_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_temporal_events_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_temporal_events_enriched_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_test_problem_finding_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_test_result_date_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-04-11-spellcheck_clinical_en_3_0.md
docs/_posts/murat-gunay/2022-04-13-spellcheck_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-04-14-spellcheck_clinical_en_2_4.md
docs/_posts/murat-gunay/2022-04-14-spellcheck_clinical_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-04-18-spellcheck_clinical_en_2_4.md
docs/_posts/murat-gunay/2022-04-19-spellcheck_clinical_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-05-10-ner_biomedical_bc2gm_en_3_0.md
docs/_posts/murat-gunay/2022-05-11-ner_biomedical_bc2gm_en_2_4.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_afriberta_base_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_afriberta_large_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_afriberta_small_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_cino_base_v2_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_cino_large_v2_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_cino_small_v2_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_fairlex_cail_minilm_zh_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_fairlex_fscs_minilm_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_indic_transformers_bn_xlmroberta_bn_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_indic_transformers_hi_xlmroberta_hi_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_indic_transformers_te_xlmroberta_te_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_marathi_roberta_mr_3_0.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_bert_subentity_ro_3_0.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_subentity_bert_ro_3_0.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_subentity_ro_3_0.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_w2v_subentity_ro_3_0.md
docs/_posts/murat-gunay/2022-07-06-ner_deid_generic_bert_ro_3_0.md
docs/_posts/murat-gunay/2022-07-08-ner_deid_generic_ro_3_0.md
docs/_posts/xusliebana/2021-01-29-deidentify_enriched_clinical_en.md
docs/_posts/xyutech/2021-09-04-ocr_table_detection_general_model_en.md
docs/_posts/xyutech/2021-12-30-layoutlmv2_funsd_en.md
docs/_posts/xyutech/2022-01-05-layoutlmv2_funsd_en.md
docs/_posts/xyutech/2022-06-09-dit_base_finetuned_rvlcdip_en_3_0.md
docs/_posts/xyutech/2022-06-12-dit_base_finetuned_rvlcdip_en_2_4.md
docs/_posts/xyutech/2022-07-20-layoutlmv2_rvl_cdip_40k_en_3_0.md
docs/_posts/2019-04-30-pos_clinical_en.md
docs/_posts/2019-06-04-deidentify_rb_en.md
docs/_posts/2020-01-28-embeddings_clinical_en.md
docs/_posts/2020-01-28-ner_crf_en.md
docs/_posts/2020-01-30-assertion_dl_en.md
docs/_posts/2020-01-30-assertion_ml_en.md
docs/_posts/2020-01-30-ner_bionlp_en.md
docs/_posts/2020-01-30-ner_clinical_en.md
docs/_posts/2020-01-31-clinical_deidentification_en.md
docs/_posts/2020-02-01-clinical_analysis_en.md
docs/_posts/2020-03-25-ner_diseases_en.md
docs/_posts/2020-03-25-ner_drugs_en.md
docs/_posts/2020-03-26-embeddings_healthcare_en.md
docs/_posts/2020-03-26-ner_healthcare_en.md
docs/_posts/2020-04-15-ner_posology_en.md
docs/_posts/2020-04-17-spellcheck_clinical_en.md
docs/_posts/2020-04-21-chunkresolve_cpt_clinical_en.md
docs/_posts/2020-04-21-chunkresolve_icd10cm_clinical_en.md
docs/_posts/2020-04-21-chunkresolve_icd10pcs_clinical_en.md
docs/_posts/2020-04-21-chunkresolve_icdo_clinical_en.md
docs/_posts/2020-04-21-ner_posology_small_en.md
docs/_posts/2020-04-22-ner_anatomy_en.md
docs/_posts/2020-04-22-ner_cancer_genetics_en.md
docs/_posts/2020-04-22-ner_cellular_en.md
docs/_posts/2020-04-22-ner_jsl_en.md
docs/_posts/2020-04-22-ner_jsl_enriched_en.md
docs/_posts/2020-04-22-ner_risk_factors_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_diseases_clinical_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_injuries_clinical_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_musculoskeletal_clinical_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_neoplasms_clinical_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_poison_ext_clinical_en.md
docs/_posts/2020-04-28-chunkresolve_icd10cm_puerile_clinical_en.md
docs/_posts/2020-05-16-chunkresolve_loinc_clinical_en.md
docs/_posts/2020-05-21-assertion_dl_large_en.md
docs/_posts/2020-05-23-ner_clinical_large_en.md
docs/_posts/2020-05-26-embeddings_scielo_150d_es.md
docs/_posts/2020-05-26-embeddings_scielo_300d_es.md
docs/_posts/2020-05-26-embeddings_scielo_50d_es.md
docs/_posts/2020-05-26-embeddings_scielowiki_150d_es.md
docs/_posts/2020-05-26-embeddings_scielowiki_300d_es.md
docs/_posts/2020-05-26-embeddings_scielowiki_50d_es.md
docs/_posts/2020-05-27-embeddings_sciwiki_150d_es.md
docs/_posts/2020-05-27-embeddings_sciwiki_300d_es.md
docs/_posts/2020-05-27-embeddings_sciwiki_50d_es.md
docs/_posts/2020-05-29-embeddings_healthcare_100d_en.md
docs/_posts/2020-06-02-embeddings_biovec_en.md
docs/_posts/2020-06-20-chunkresolve_snomed_findings_clinical_en.md
docs/_posts/2020-06-24-chunkresolve_rxnorm_xsmall_clinical_en.md
docs/_posts/2020-07-08-ner_diag_proc_es.md
docs/_posts/2020-07-08-ner_neoplasms_es.md
docs/_posts/2020-07-27-chunkresolve_rxnorm_cd_clinical_en.md
docs/_posts/2020-07-27-chunkresolve_rxnorm_sbd_clinical_en.md
docs/_posts/2020-07-27-chunkresolve_rxnorm_scd_clinical_en.md
docs/_posts/2020-08-04-deidentify_large_en.md
docs/_posts/2020-08-19-explain_clinical_doc_carp_en.md
docs/_posts/2020-08-19-explain_clinical_doc_cra_en.md
docs/_posts/2020-09-03-re_drug_drug_interaction_clinical_en.md
docs/_posts/2020-09-06-chunkresolve_ICD10GM_de.md
docs/_posts/2020-09-06-w2v_cc_300d_de.md
docs/_posts/2020-09-13-sentence_detector_dl_healthcare_en.md
docs/_posts/2020-09-16-chunkresolve_athena_conditions_healthcare_en.md
docs/_posts/2020-09-21-ner_chemprot_clinical_en.md
docs/_posts/2020-09-21-ner_human_phenotype_gene_clinical_en.md
docs/_posts/2020-09-21-ner_human_phenotype_go_clinical_en.md
docs/_posts/2020-09-23-assertion_dl_healthcare_en.md
docs/_posts/2020-09-24-re_clinical_en.md
docs/_posts/2020-09-28-ner_healthcare_de.md
docs/_posts/2020-09-28-re_temporal_events_clinical_en.md
docs/_posts/2020-09-28-re_temporal_events_enriched_clinical_en.md
docs/_posts/2020-09-30-classifierdl_ade_biobert.md
docs/_posts/2020-09-30-explain_clinical_doc_era_en.md
docs/_posts/2020-09-30-re_human_phenotype_gene_clinical_en.md
docs/_posts/2020-11-04-ner_anatomy_coarse_biobert_en.md
docs/_posts/2020-11-04-ner_anatomy_coarse_en.md
docs/_posts/2020-11-12-classifierdl_pico_biobert_en.md
docs/_posts/2020-11-27-sbiobert_base_cased_mli_en.md
docs/_posts/2020-11-27-sbiobertresolve_cpt_en.md
docs/_posts/2020-11-27-sbiobertresolve_icd10cm_en.md
docs/_posts/2020-11-27-sbiobertresolve_icd10pcs_en.md
docs/_posts/2020-11-27-sbiobertresolve_icdo_en.md
docs/_posts/2020-11-27-sbiobertresolve_rxnorm_en.md
docs/_posts/2020-11-27-sbiobertresolve_snomed_auxConcepts_en.md
docs/_posts/2020-11-27-sbiobertresolve_snomed_auxConcepts_int_en.md
docs/_posts/2020-11-27-sbiobertresolve_snomed_findings_en.md
docs/_posts/2020-11-27-sbiobertresolve_snomed_findings_int_en.md
docs/_posts/2020-11-27-sbluebert_base_uncased_mli_en.md
docs/_posts/2020-12-11-sbiobertresolve_rxcui_en.md
docs/_posts/2020-12-13-sbiobertresolve_icd10cm_augmented_en.md
docs/_posts/2020-12-16-classifierdl_gender_biobert_en.md
docs/_posts/2020-12-16-classifierdl_gender_sbert_en.md
docs/_posts/2021-01-18-jsl_assertion_wip_en.md
docs/_posts/2021-01-18-jsl_assertion_wip_large_en.md
docs/_posts/2021-01-18-jsl_ner_wip_clinical_en.md
docs/_posts/Ahmetemintek/2021-12-24-sbiobertresolve_loinc_cased_en.md
docs/_posts/Ahmetemintek/2022-02-26-sbiobertresolve_snomed_findings_aux_concepts_en_3_0.md
docs/_posts/Ahmetemintek/2022-03-31-drug_action_treatment_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-04-01-normalized_section_header_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-04-04-drug_action_treatment_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-04-04-normalized_section_header_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-05-11-abbreviation_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-05-27-rct_binary_classifier_biobert_en_3_0.md
docs/_posts/Ahmetemintek/2022-05-27-rct_binary_classifier_use_en_3_0.md
docs/_posts/Ahmetemintek/2022-06-07-rxnorm_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-06-24-rxnorm_umls_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-05-sbiobertresolve_umls_clinical_drugs_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-05-sbiobertresolve_umls_findings_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-06-umls_clinical_drugs_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-08-umls_clinical_findings_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-11-umls_disease_syndrome_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-11-umls_drug_substance_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-11-umls_major_concepts_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-25-umls_drug_substance_resolver_pipeline_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-25-umls_major_concepts_resolver_pipeline_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-26-umls_clinical_findings_resolver_pipeline_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-26-umls_disease_syndrome_resolver_pipeline_en_3_0.md
docs/_posts/Ahmetemintek/2022-07-26-umls_drug_resolver_pipeline_en_3_0.md
docs/_posts/Ahmetemintek/2022-08-03-explain_clinical_doc_radiology_en_3_0.md
docs/_posts/Ahmetemintek/2022-08-23-drug_ade_mapper_en.md
docs/_posts/Ahmetemintek/2022-09-15-assertion_jsl_augmented_en.md
docs/_posts/Ahmetemintek/2022-09-29-rxnorm_normalized_mapper_en.md
docs/_posts/Ahmetemintek/2022-09-30-icd10_icd9_mapper_en.md
docs/_posts/Ahmetemintek/2022-09-30-icd10_icd9_mapping_en.md
docs/_posts/Ahmetemintek/2022-09-30-icd9_icd10_mapper_en.md
docs/_posts/Ahmetemintek/2022-09-30-icd9_mapper_en.md
docs/_posts/Ahmetemintek/2022-09-30-icd9_resolver_pipeline_en.md
docs/_posts/Ahmetemintek/2022-09-30-sbiobertresolve_icd9_en.md
docs/_posts/Ahmetemintek/2022-10-12-cvx_code_mapper_en.md
docs/_posts/Ahmetemintek/2022-10-12-cvx_name_mapper_en.md
docs/_posts/Ahmetemintek/2022-10-12-cvx_resolver_pipeline_en.md
docs/_posts/Ahmetemintek/2022-10-12-sbiobertresolve_cvx_en.md
docs/_posts/C-K-Loan/2021-03-29-recognize_entities_posology_en.md
docs/_posts/Cabir40/2022-03-01-sbiobertresolve_atc_en_2_4.md
docs/_posts/Cabir40/2022-03-01-sbiobertresolve_atc_en_3_0.md
docs/_posts/Cabir40/2022-03-03-clinical_deidentification_en_2_4.md
docs/_posts/Cabir40/2022-03-03-clinical_deidentification_en_3_0.md
docs/_posts/Cabir40/2022-03-23-assertion_dl_biobert_scope_L10R10_en_3_0.md
docs/_posts/Cabir40/2022-03-24-assertion_dl_biobert_scope_L10R10_en_2_4.md
docs/_posts/Cabir40/2022-03-31-explain_clinical_doc_radiology_en_3_0.md
docs/_posts/Cabir40/2022-04-01-explain_clinical_doc_medication_en_3_0.md
docs/_posts/Cabir40/2022-04-25-sbiobertresolve_rxnorm_action_treatment_en_2_4.md
docs/_posts/Cabir40/2022-05-10-sbiobertresolve_cpt_procedures_measurements_augmented_en_3_0.md
docs/_posts/Cabir40/2022-05-11-sbiobertresolve_icd10cm_slim_billable_hcc_en_3_0.md
docs/_posts/Cabir40/2022-05-12-sbiobertresolve_icd10cm_slim_normalized_en_3_0.md
docs/_posts/Cabir40/2022-06-22-ner_biomedical_bc2gm_pipeline_en_3_0.md
docs/_posts/Cabir40/2022-06-27-ner_clinical_trials_abstracts_pipeline_en_3_0.md
docs/_posts/Cabir40/2022-06-28-clinical_deidentification_ro_3_0.md
docs/_posts/Cabir40/2022-07-26-bert_sequence_classifier_exact_age_reddit_en_3_0.md
docs/_posts/Cabir40/2022-07-26-bert_sequence_classifier_self_reported_age_tweet_en_3_0.md
docs/_posts/Cabir40/2022-07-29-ner_living_species_300_es_3_0.md
docs/_posts/Cabir40/2022-08-12-ner_clinical_bert_ro_3_0.md
docs/_posts/Cabir40/2022-08-15-ner_deid_generic_bert_ro_3_0.md
docs/_posts/Cabir40/2022-09-14-clinical_deidentification_en.md
docs/_posts/Cabir40/2022-09-16-clinical_deidentification_glove_augmented_en.md
docs/_posts/Damla-Gurbaz/2022-03-22-bert_token_classifier_drug_development_trials_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-06-bert_sequence_classifier_binary_rct_biobert_pipeline_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-06-rct_binary_classifier_biobert_pipeline_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-06-rct_binary_classifier_use_pipeline_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-abbreviation_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-drug_brandname_ndc_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icd10cm_snomed_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icd10cm_umls_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icdo_snomed_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-mesh_umls_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-normalized_section_header_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-rxnorm_umls_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-snomed_icd10cm_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-snomed_icdo_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-icd10cm_snomed_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-icd10cm_umls_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-icdo_snomed_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-mesh_umls_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-rxnorm_action_treatment_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-rxnorm_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-rxnorm_ndc_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-rxnorm_ndc_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-rxnorm_umls_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-snomed_icd10cm_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-snomed_icdo_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-snomed_umls_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-27-snomed_umls_mapping_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-28-drug_action_treatment_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-07-27-bert_sequence_classifier_ade_augmented_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-07-27-bert_token_classifier_ner_ade_binary_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-07-29-bert_token_classifier_ade_tweet_binary_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-08-10-explain_clinical_doc_medication_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-09-01-medication_resolver_pipeline_en.md
docs/_posts/Damla-Gurbaz/2022-09-01-medication_resolver_transform_pipeline_en.md
docs/_posts/HashamUlHaq/2020-12-08-ner_posology_greedy_en.md
docs/_posts/HashamUlHaq/2020-12-14-ner_drugs_greedy_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_ade_biobert_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_ade_clinicalbert_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_ade_conversational_biobert_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_gender_biobert_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_gender_sbert_en.md
docs/_posts/HashamUlHaq/2021-01-21-classifierdl_pico_biobert_en.md
docs/_posts/HashamUlHaq/2021-01-26-assertion_dl_biobert_en.md
docs/_posts/HashamUlHaq/2021-01-26-assertion_dl_en.md
docs/_posts/HashamUlHaq/2021-01-26-assertion_dl_healthcare_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_bodypart_direction_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_bodypart_problem_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_bodypart_procedure_test_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_chemprot_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_clinical_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_date_clinical_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_drug_drug_interaction_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_human_phenotype_gene_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-04-redl_temporal_events_biobert_en.md
docs/_posts/HashamUlHaq/2021-02-06-sbiobertresolve_icd10cm_augmented_billable_hcc_en.md
docs/_posts/HashamUlHaq/2021-02-19-t5_base_mediqa_mnli_en.md
docs/_posts/HashamUlHaq/2021-02-24-re_test_result_date_en.md
docs/_posts/HashamUlHaq/2021-03-01-ner_events_admission_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-16-sentence_detector_dl_healthcare_en.md
docs/_posts/HashamUlHaq/2021-03-31-jsl_ner_wip_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-jsl_ner_wip_greedy_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_anatomy_coarse_biobert_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_anatomy_coarse_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_anatomy_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_aspect_based_sentiment_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_bionlp_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_cancer_genetics_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_cellular_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_chemprot_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_clinical_large_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_deid_augmented_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_deid_enriched_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_deid_large_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_deid_synthetic_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_deidentify_dl_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_diag_proc_es.md
docs/_posts/HashamUlHaq/2021-03-31-ner_diseases_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_drugs_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_drugs_greedy_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_drugs_large_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_events_admission_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_events_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_healthcare_de.md
docs/_posts/HashamUlHaq/2021-03-31-ner_human_phenotype_gene_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_human_phenotype_go_clinical_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_jsl_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_jsl_enriched_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_neoplasms_es.md
docs/_posts/HashamUlHaq/2021-03-31-ner_posology_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_posology_greedy_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_posology_large_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_posology_small_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_radiology_en.md
docs/_posts/HashamUlHaq/2021-03-31-ner_risk_factors_en.md
docs/_posts/HashamUlHaq/2021-04-01-explain_clinical_doc_ade_en.md
docs/_posts/HashamUlHaq/2021-04-01-explain_clinical_doc_carp_en.md
docs/_posts/HashamUlHaq/2021-04-01-explain_clinical_doc_era_en.md
docs/_posts/HashamUlHaq/2021-04-01-jsl_ner_wip_modifier_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-01-jsl_rd_ner_wip_greedy_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_ade_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_ade_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_ade_clinicalbert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_ade_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_anatomy_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_bacterial_species_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_bionlp_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_cellular_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_chemicals_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_chemprot_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_clinical_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_deid_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_deid_enriched_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_deid_sd_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_deid_sd_large_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_diseases_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_diseases_large_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_events_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_events_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_financial_contract_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_healthcare_slim_de.md
docs/_posts/HashamUlHaq/2021-04-01-ner_human_phenotype_gene_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_human_phenotype_go_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_jsl_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_jsl_enriched_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_measurements_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_medmentions_coarse_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_posology_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_posology_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_posology_large_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_radiology_wip_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_risk_factors_biobert_en.md
docs/_posts/HashamUlHaq/2021-04-01-ner_traffic_de.md
docs/_posts/HashamUlHaq/2021-04-01-nerdl_tumour_demo_en.md
docs/_posts/HashamUlHaq/2021-04-01-recognize_entities_posology_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_cpt_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_diseases_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_hcc_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_injuries_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_musculoskeletal_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10cm_neoplasms_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icd10pcs_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_icdo_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-02-chunkresolve_loinc_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_ICD10GM_2021_de.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_cd_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_in_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_in_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_sbd_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_scd_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_scdc_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_scdc_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_rxnorm_xsmall_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-16-chunkresolve_snomed_findings_clinical_en.md
docs/_posts/HashamUlHaq/2021-04-19-re_test_problem_finding_en.md
docs/_posts/HashamUlHaq/2021-04-21-ner_healthcare_en.md
docs/_posts/HashamUlHaq/2021-04-29-sbiobertresolve_loinc_en.md
docs/_posts/HashamUlHaq/2021-04-29-sbluebertresolve_loinc_en.md
docs/_posts/HashamUlHaq/2021-04-30-sbiobertresolve_umls_findings_en.md
docs/_posts/HashamUlHaq/2021-05-02-sbiobertresolve_umls_major_concepts_en.md
docs/_posts/HashamUlHaq/2021-05-05-sbiobertresolve_HPO_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_medium_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_medium_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_mini_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_mini_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_tiny_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbert_jsl_tiny_uncased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbiobert_jsl_cased_en.md
docs/_posts/HashamUlHaq/2021-05-14-sbiobert_jsl_umls_cased_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_HPO_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_cpt_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_icd10cm_augmented_billable_hcc_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_icd10cm_augmented_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_icd10cm_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_icd10pcs_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_icdo_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_loinc_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_rxcui_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_rxnorm_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_snomed_auxConcepts_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_snomed_auxConcepts_int_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_snomed_findings_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_snomed_findings_int_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_umls_findings_en.md
docs/_posts/HashamUlHaq/2021-05-16-sbiobertresolve_umls_major_concepts_en.md
docs/_posts/HashamUlHaq/2021-05-17-sbiobertresolve_icd10cm_slim_normalized_en.md
docs/_posts/HashamUlHaq/2021-05-21-sbertresolve_icd10cm_slim_billable_hcc_med_en.md
docs/_posts/HashamUlHaq/2021-05-21-sbiobertresolve_icd10cm_slim_billable_hcc_en.md
docs/_posts/HashamUlHaq/2021-05-30-sbiobertresolve_cpt_augmented_en.md
docs/_posts/HashamUlHaq/2021-05-30-sbiobertresolve_cpt_procedures_augmented_en.md
docs/_posts/HashamUlHaq/2021-05-30-sbiobertresolve_hcc_augmented_en.md
docs/_posts/HashamUlHaq/2021-06-30-ner_deid_generic_augmented_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_medium_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_medium_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_mini_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_mini_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_tiny_umls_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbert_jsl_tiny_uncased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbiobert_jsl_cased_en.md
docs/_posts/HashamUlHaq/2021-06-30-sbiobert_jsl_umls_cased_en.md
docs/_posts/HashamUlHaq/2021-07-01-icd10cm_umls_mapping_en.md
docs/_posts/HashamUlHaq/2021-07-01-mesh_umls_mapping_en.md
docs/_posts/HashamUlHaq/2021-07-01-rxnorm_mesh_mapping_en.md
docs/_posts/HashamUlHaq/2021-07-01-rxnorm_umls_mapping_en.md
docs/_posts/HashamUlHaq/2021-07-01-snomed_umls_mapping_en.md
docs/_posts/HashamUlHaq/2021-07-02-sbiobertresolve_cpt_procedures_measurements_augmented_en.md
docs/_posts/HashamUlHaq/2021-07-02-sbiobertresolve_icdo_base_en.md
docs/_posts/HashamUlHaq/2021-07-12-re_ade_clinical_en.md
docs/_posts/HashamUlHaq/2021-07-12-redl_ade_biobert_en.md
docs/_posts/HashamUlHaq/2021-07-15-explain_clinical_doc_ade_en.md
docs/_posts/HashamUlHaq/2021-07-16-re_ade_biobert_en.md
docs/_posts/HashamUlHaq/2021-07-26-jsl_ner_wip_greedy_biobert_en.md
docs/_posts/HashamUlHaq/2021-07-26-jsl_rd_ner_wip_greedy_biobert_en.md
docs/_posts/HashamUlHaq/2021-08-11-sentence_detector_dl_healthcare_en.md
docs/_posts/HashamUlHaq/2021-08-13-ner_jsl_slim_en.md
docs/_posts/HashamUlHaq/2021-09-01-ner_posology_experimental_en.md
docs/_posts/HashamUlHaq/2021-09-05-ner_jsl_biobert_en.md
docs/_posts/HashamUlHaq/2021-09-29-sbiobertresolve_icd10cm_generalised_en.md
docs/_posts/HashamUlHaq/2021-09-30-ner_chexpert_en.md
docs/_posts/HashamUlHaq/2021-10-03-sbiobertresolve_umls_findings_en.md
docs/_posts/HashamUlHaq/2021-10-03-sbiobertresolve_umls_major_concepts_en.md
docs/_posts/HashamUlHaq/2021-10-11-sbiobertresolve_umls_clinical_drugs_en.md
docs/_posts/HashamUlHaq/2021-10-11-sbiobertresolve_umls_disease_syndrome_en.md
docs/_posts/HashamUlHaq/2021-10-22-ner_jsl_enriched_en.md
docs/_posts/HashamUlHaq/2021-11-05-ner_covid_trials_en.md
docs/_posts/HashamUlHaq/2021-11-11-sbiobertresolve_snomed_procedures_measurements_en.md
docs/_posts/HashamUlHaq/2021-11-15-ner_nihss_en.md
docs/_posts/HashamUlHaq/2021-11-15-sbiobertresolve_clinical_snomed_procedures_measurements_en.md
docs/_posts/HashamUlHaq/2021-11-16-redl_nihss_biobert_en.md
docs/_posts/HashamUlHaq/2021-11-26-ner_biomarker_en.md
docs/_posts/HashamUlHaq/2021-12-06-sbiobertresolve_umls_drug_substance_en.md
docs/_posts/HashamUlHaq/2021-12-17-bert_token_classifier_drug_development_trials_en.md
docs/_posts/HashamUlHaq/2022-02-01-ner_supplement_clinical_en.md
docs/_posts/HashamUlHaq/2022-02-01-sbiobertresolve_clinical_abbreviation_acronym_en.md
docs/_posts/HashamUlHaq/2022-02-08-ner_nature_nero_clinical_en.md
docs/_posts/HashamUlHaq/2022-06-18-bert_token_classifier_drug_development_trials_en_3_0.md
docs/_posts/HashamUlHaq/2022-07-27-re_ade_conversational_en_3_0.md
docs/_posts/Meryem1425/2022-03-04-clinical_deidentification_glove_en_3_0.md
docs/_posts/Meryem1425/2022-03-21-bert_token_classifier_ner_jsl_en_2_4.md
docs/_posts/Meryem1425/2022-06-06-sbiobertresolve_icdo_augmented_en_3_0.md
docs/_posts/Meryem1425/2022-07-28-bert_sequence_classifier_drug_reviews_webmd_en_3_0.md
docs/_posts/Meryem1425/2022-08-04-bert_sequence_classifier_treatment_changes_sentiment_tweet_en_3_0.md
docs/_posts/albertoandreottiATgmail/2021-03-30-spellcheck_clinical_en.md
docs/_posts/albertoandreottiATgmail/2021-09-10-redl_bodypart_procedure_test_biobert_en.md
docs/_posts/alierenak/2022-07-28-classifierdl_vaccine_sentiment_en_3_0.md
docs/_posts/alierenak/2022-08-01-bert_sequence_classifier_covid_sentiment_en_3_0.md
docs/_posts/alierenak/2022-08-09-bert_sequence_classifier_depression_en_3_0.md
docs/_posts/alierenak/2022-08-09-bert_sequence_classifier_depression_twitter_en_3_0.md
docs/_posts/alierenak/2022-08-10-bert_sequence_classifier_depression_binary_en_3_0.md
docs/_posts/alierenak/2022-08-10-bert_sequence_classifier_health_mentions_bert_de_3_0.md
docs/_posts/alierenak/2022-08-10-bert_sequence_classifier_health_mentions_gbert_de_3_0.md
docs/_posts/alierenak/2022-08-10-bert_sequence_classifier_health_mentions_gbert_large_de_3_0.md
docs/_posts/alierenak/2022-08-10-bert_sequence_classifier_health_mentions_medbert_de_3_0.md
docs/_posts/aydinmyilmaz/2021-01-18-ner_radiology_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_directions_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_problem_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_proceduretest_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_date_clinical_en.md
docs/_posts/aydinmyilmaz/2021-01-20-ner_deid_augmented_en.md
docs/_posts/aydinmyilmaz/2021-01-28-deidentify_dl_en.md
docs/_posts/bunyamin-polat/2022-03-22-bert_token_classifier_drug_development_trials_en_2_4.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_bert_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_bert_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_biobert_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_roberta_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_roberta_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_fr_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_ro_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_ca_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_fr_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_gl_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-26-bert_token_classifier_ner_living_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-30-clinical_deidentification_glove_augmented_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-30-explain_clinical_doc_ade_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_anatem_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc2gm_gene_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc4chemd_chemicals_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc5cdr_chemicals_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc5cdr_disease_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_jnlpba_cellular_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_linnaeus_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_ncbi_disease_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_de.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_en.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_fr.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_it.md
docs/_posts/bunyamin-polat/2022-10-25-legner_indian_court_judgement_en.md
docs/_posts/bunyamin-polat/2022-10-25-legner_indian_court_preamble_en.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_de.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_en.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_fr.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_it.md
docs/_posts/dcecchini/2021-01-29-ner_drugs_large_en.md
docs/_posts/dcecchini/2021-07-23-cantemist_scielowiki_es.md
docs/_posts/dcecchini/2021-07-26-meddroprof_scielowiki_es.md
docs/_posts/egenc/2022-01-03-bert_token_classifier_ner_bionlp_en.md
docs/_posts/egenc/2022-01-04-bert_token_classifier_ner_ade_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_anatomy_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_cellular_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_chemicals_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_chemprot_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_clinical_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_deid_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_drugs_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_jsl_en.md
docs/_posts/egenc/2022-01-06-bert_token_classifier_ner_jsl_slim_en.md
docs/_posts/egenc/2022-01-07-bert_token_classifier_ner_bacteria_en.md
docs/_posts/egenc/2022-01-17-sbertresolve_ner_model_finder_en.md
docs/_posts/egenc/2022-01-18-ner_profiling_biobert_en.md
docs/_posts/egenc/2022-01-18-ner_profiling_clinical_en.md
docs/_posts/egenc/2022-01-18-sbiobertresolve_icd10cm_augmented_en.md
docs/_posts/egenc/2022-01-18-sbiobertresolve_loinc_augmented_en.md
docs/_posts/egenc/2022-01-18-sbiobertresolve_mesh_en.md
docs/_posts/egenc/2022-01-18-sbiobertresolve_snomed_drug_en.md
docs/_posts/egenc/2022-01-18-sbluebertresolve_loinc_uncased_en.md
docs/_posts/egenc/2022-01-21-ner_model_finder_en.md
docs/_posts/egenc/2022-01-21-ner_profiling_biobert_en.md
docs/_posts/egenc/2022-01-21-sbiobertresolve_icd10cm_augmented_en.md
docs/_posts/egenc/2022-02-28-sbiobertresolve_hcpcs_en_2_4.md
docs/_posts/egenc/2022-02-28-sbiobertresolve_hcpcs_en_3_0.md
docs/_posts/gadde5300/2022-02-09-bert_token_classifier_ner_supplement_en.md
docs/_posts/gadde5300/2022-03-01-bert_sequence_classifier_rct_biobert_en_2_4.md
docs/_posts/gadde5300/2022-03-01-bert_sequence_classifier_rct_biobert_en_3_0.md
docs/_posts/gadde5300/2022-03-17-assertion_dl_scope_L10R10_en_2_4.md
docs/_posts/gadde5300/2022-03-17-assertion_dl_scope_L10R10_en_3_0.md
docs/_posts/gadde5300/2022-04-25-bert_sequence_classifier_binary_rct_biobert_en_3_0.md
docs/_posts/gadde5300/2022-10-17-legner_confidentiality_en.md
docs/_posts/gadde5300/2022-10-17-legner_warranty_en.md
docs/_posts/gadde5300/2022-10-18-legre_confidentiality_en.md
docs/_posts/gadde5300/2022-10-19-legre_warranty_en.md
docs/_posts/galiph/2021-12-21-jsl_sbert_medium_rxnorm_en.md
docs/_posts/galiph/2021-12-23-sbert_jsl_medium_rxnorm_uncased_en.md
docs/_posts/galiph/2021-12-23-sbiobert_jsl_rxnorm_cased_en.md
docs/_posts/galiph/2021-12-27-sbiobertresolve_jsl_rxnorm_augmented_en.md
docs/_posts/galiph/2021-12-28-sbertresolve_jsl_rxnorm_augmented_med_en.md
docs/_posts/galiph/2021-12-28-sbiobertresolve_rxnorm_augmented_cased_en.md
docs/_posts/galiph/2021-12-28-sbluebertresolve_rxnorm_augmented_uncased_en.md
docs/_posts/galiph/2022-01-03-sbert_jsl_medium_rxnorm_uncased_en.md
docs/_posts/galiph/2022-01-03-sbiobertresolve_rxnorm_augmented_en.md
docs/_posts/galiph/2022-01-06-clinical_deidentification_de.md
docs/_posts/galiph/2022-01-06-ner_deid_generic_de.md
docs/_posts/galiph/2022-01-06-ner_deid_subentity_de.md
docs/_posts/galiph/2022-01-08-clinical_deidentification_de.md
docs/_posts/galiph/2022-02-09-sbiobertresolve_rxnorm_augmented_re_en.md
docs/_posts/galiph/2022-03-03-clinical_deidentification_de_3_0.md
docs/_posts/galiph/2022-03-03-german_deid_pipeline_spark24_de_2_4.md
docs/_posts/galiph/2022-04-18-sbiobertresolve_ndc_en_2_4.md
docs/_posts/galiph/2022-05-08-rxnorm_action_treatment_mapper_en_3_0.md
docs/_posts/galiph/2022-05-09-rxnorm_ndc_mapper_en_3_0.md
docs/_posts/galiph/2022-05-11-drug_brandname_ndc_mapper_en_3_0.md
docs/_posts/galiph/2022-05-20-rxnorm_ndc_mapper_en_3_0.md
docs/_posts/galiph/2022-07-28-ner_medication_pipeline_en_3_0.md
docs/_posts/galiph/2022-08-01-medication_resolver_pipeline_en_3_0.md
docs/_posts/galiph/2022-08-01-medication_resolver_transform_pipeline_en_3_0.md
docs/_posts/gokhanturer/2022-07-26-ner_living_species_300_es_3_0.md
docs/_posts/gokhanturer/2022-07-28-bert_sequence_classifier_self_reported_partner_violence_tweet_en_3_0.md
docs/_posts/gokhanturer/2022-07-29-bert_sequence_classifier_self_reported_vaccine_status_tweet_en_3_0.md
docs/_posts/gokhanturer/2022-10-15-finre_has_ticker_en.md
docs/_posts/gpirge/2022-06-28-ner_pathogen_en_3_0.md
docs/_posts/gpirge/2022-06-29-ner_pathogen_pipeline_en_3_0.md
docs/_posts/gpirge/2022-07-28-bert_sequence_classifier_self_reported_symptoms_tweet_es_3_0.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_disease_mentions_tweet_es_3_0.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_ner_pathogen_en_3_0.md
docs/_posts/gpirge/2022-08-08-bert_sequence_classifier_health_mandates_premise_tweet_en_3_0.md
docs/_posts/gpirge/2022-08-08-bert_sequence_classifier_health_mandates_stance_tweet_en_3_0.md
docs/_posts/gpirge/2022-08-11-bert_token_classifier_negation_uncertainty_es_3_0.md
docs/_posts/gpirge/2022-08-11-bert_token_classifier_ner_clinical_trials_abstracts_es_3_0.md
docs/_posts/gpirge/2022-08-11-bert_token_classifier_pharmacology_es_3_0.md
docs/_posts/gpirge/2022-08-12-ner_clinical_trials_abstracts_es_3_0.md
docs/_posts/gpirge/2022-08-13-ner_negation_uncertainty_es_3_0.md
docs/_posts/gpirge/2022-08-13-ner_pharmacology_es_3_0.md
docs/_posts/gpirge/2022-08-14-disease_mentions_tweet_es_3_0.md
docs/_posts/hsaglamlar/2022-06-30-ner_clinical_bert_ro_3_0.md
docs/_posts/hsaglamlar/2022-07-01-ner_clinical_ro_3_0.md
docs/_posts/hsaglamlar/2022-07-29-bert_sequence_classifier_self_reported_stress_tweet_en_3_0.md
docs/_posts/iamvarol/2021-11-23-sbiobertresolve_loinc_augmented_en.md
docs/_posts/iamvarol/2021-12-31-sbluebertresolve_loinc_uncased_en.md
docs/_posts/josejuanmartinez/2021-11-03-robertaresolve_snomed_es.md
docs/_posts/josejuanmartinez/2021-11-04-roberta_ner_diag_proc_es.md
docs/_posts/josejuanmartinez/2021-11-05-bert_sequence_classifier_question_statement_clinical_en.md
docs/_posts/josejuanmartinez/2022-01-17-ner_deid_generic_roberta_es.md
docs/_posts/josejuanmartinez/2022-01-17-ner_deid_subentity_roberta_es.md
docs/_posts/josejuanmartinez/2022-01-18-ner_deid_generic_es.md
docs/_posts/josejuanmartinez/2022-01-18-ner_deid_subentity_es.md
docs/_posts/josejuanmartinez/2022-01-24-clinical_deidentification_es.md
docs/_posts/josejuanmartinez/2022-02-11-clinical_deidentification_es.md
docs/_posts/josejuanmartinez/2022-02-14-clinical_deidentification_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_generic_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_generic_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_subentity_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_subentity_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-clinical_deidentification_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_generic_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_generic_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_subentity_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_subentity_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-17-clinical_deidentification_es.md
docs/_posts/josejuanmartinez/2022-03-02-clinical_deidentification_es_2_4.md
docs/_posts/josejuanmartinez/2022-03-03-clinical_deidentification_augmented_es_2_4.md
docs/_posts/josejuanmartinez/2022-03-22-clinical_deidentification_glove_augmented_en_3_0.md
docs/_posts/josejuanmartinez/2022-04-05-re_zeroshot_biobert_en_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_generic_pt_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_subentity_pt_3_0.md
docs/_posts/josejuanmartinez/2022-04-14-clinical_deidentification_pt_3_0.md
docs/_posts/josejuanmartinez/2022-06-21-clinical_deidentification_pt_3_0.md
docs/_posts/josejuanmartinez/2022-08-09-finclf_bank_complaints_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finclf_distilroberta_sentiment_analysis_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finel_crunchbase_companynames_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finmapper_crunchbase_companyname_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finmapper_nasdaq_companyname_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finmapper_nasdaq_ticker_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finner_deid_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finner_roberta_ticker_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finner_ticker_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-finqa_roberta_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legclf_conventions_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legclf_human_rights_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legel_crunchbase_companynames_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legmapper_crunchbase_companyname_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legner_cuad_silver_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legner_deid_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legqa_bert_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legqa_bert_large_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-09-legqa_roberta_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_business_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_controls_procedures_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_equity_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_executives_compensation_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_executives_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_exhibits_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_financial_conditions_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_financial_statements_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_form_10k_summary_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_legal_proceedings_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_market_risk_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_properties_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_risk_factors_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-finclf_security_ownership_item_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_absence_of_certain_changes_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_acceleration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_access_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_accounting_terms_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_adjustments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_agreements_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_amendments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_application_of_proceeds_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_appointment_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_approvals_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_arbitration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_assignments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_authority_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_authorization_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_auto_renewal_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_background_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_bank_accounts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_bankruptcy_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_base_salary_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_benefits_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_bereavement_leave_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_binding_effect_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_bonus_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_books_and_records_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_brokers_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_cancellation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_capitalization_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_captions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_cause_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_certain_definitions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_certificates_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_change_in_control_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_change_of_control_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_closing_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_collateral_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_compensation_and_benefits_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_compensation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_compliance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_compliance_with_laws_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_condemnation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_conditions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_conditions_to_effectiveness_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_conduct_of_business_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_confidential_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_conflict_of_interest_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_consents_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_consideration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_construction_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_contracts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_contribution_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_cooperation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_corporate_existence_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_costs_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_counterparts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_covenants_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_currency_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_death_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_defaults_and_remedies_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_defaults_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_definitions_and_interpretation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_definitions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_delegation_of_duties_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_delivery_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_disability_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_disclaimer_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_disclosure_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_dispute_resolution_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_disputes_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_dissolution_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_distributions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_dividends_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_documents_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_duration_and_termination_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_duration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_duties_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_effective_date_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_effectiveness_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_employees_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_employment_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_erisa_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_exceptions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_exclusions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_exclusivity_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_execution_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_execution_in_counterparts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_exercise_of_option_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_exhibits_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_expenses_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_fees_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_financial_information_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_financial_statements_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_fiscal_year_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_force_majeure_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_fractional_shares_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_full_disclosure_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_further_assurances_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_general_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_good_reason_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_grant_of_option_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_grant_of_security_interest_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_guarantee_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_headings_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_holidays_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_illegality_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_in_witness_whereof_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_increased_costs_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_indebtedness_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_indemnification_by_the_company_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_indemnification_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_indemnity_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_independent_contractor_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_information_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_injunctive_relief_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_insolvency_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_inspection_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_insurance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_integration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_intellectual_property_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_interest_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_interpretation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_introduction_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_investment_company_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_investments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_judgments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_jurisdiction_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_labor_matters_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_laws_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_legal_proceedings_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_legends_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_letters_of_credit_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_liabilities_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_liability_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_licenses_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_liens_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_limitations_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_listing_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_litigation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_loans_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_maintenance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_management_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_marketing_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_material_contracts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_meetings_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_merger_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_miscellaneous_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_modification_and_waiver_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_modifications_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_name_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_negative_covenants_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_assignment_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_conflicts_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_default_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_material_adverse_change_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_solicitation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_strict_construction_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_third_party_beneficiaries_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_violation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_no_waiver_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_non_competition_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_non_discrimination_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_non_disparagement_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_non_solicitation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_notices_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_notification_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_now_therefore_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_obligations_absolute_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_officers_certificate_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_officers_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_optional_renewal_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_organization_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_other_benefits_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_other_remedies_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_ownership_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_parking_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_partial_invalidity_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_participations_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_parties_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_parties_in_interest_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_payments_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_performance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_permits_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_persons_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_position_and_duties_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_powers_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_preamble_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_procedures_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_proprietary_rights_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_provisions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_public_announcements_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_publicity_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_purchase_and_sale_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_purchase_price_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_purpose_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_real_property_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_recitals_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_recognition_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_records_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_redemption_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_registration_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_registration_expenses_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_registration_rights_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_reimbursements_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_reinstatement_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_relationship_of_the_parties_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_release_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_reliance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_remedies_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_remedies_cumulative_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_rent_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_reporting_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_reports_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_representations_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_resignation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_restrictions_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_restrictions_on_transfer_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_right_of_setoff_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_rules_of_construction_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_salary_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_scope_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_section_headings_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_security_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_security_interest_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_seniority_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_services_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_set_off_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_severability_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_severance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_sick_leave_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_solvency_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_special_terms_and_conditions_of_trust_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_specific_performance_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_standard_of_care_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_standard_terms_and_conditions_of_trust_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_stock_options_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_subordination_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_subrogation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_subsidiaries_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_successors_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_support_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_tax_returns_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_tax_withholding_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_taxes_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_term_and_termination_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_term_of_employment_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_termination_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_termination_of_agreement_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_termination_of_employment_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_terms_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_the_closing_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_the_merger_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_therefore_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_third_party_beneficiaries_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_time_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_title_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_transactions_with_affiliates_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_transfer_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_transfers_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_trustee_may_file_proofs_of_claim_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_undertaking_for_costs_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_usa_patriot_act_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_use_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_use_of_proceeds_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_utilities_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_vacation_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_validity_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_vesting_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_voting_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_waiver_of_jury_trial_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_waivers_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_warranty_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_whereas_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-10-legclf_witnesseth_clause_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-12-legner_bert_grants_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-12-legner_headers_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-12-legner_whereas_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-12-legre_contract_doc_parties_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-16-finner_arabert_arabic_ar_3_2.md
docs/_posts/josejuanmartinez/2022-08-16-legner_contract_doc_parties_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-16-legner_signers_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-finassertion_competitors_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-finner_10k_summary_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-finner_orgs_prods_alias_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-finre_org_prod_alias_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-legner_orgs_prods_alias_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-17-legre_org_prod_alias_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-18-finmapper_edgar_companyname_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-18-finmapper_edgar_irs_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-18-legmapper_edgar_companyname_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-18-legmapper_edgar_irs_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-22-finre_zero_shot_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-22-legner_obligations_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-22-legre_zero_shot_en_3_2.md
docs/_posts/josejuanmartinez/2022-08-24-legpipe_obligations_en.md
docs/_posts/josejuanmartinez/2022-08-24-legpipe_whereas_en.md
docs/_posts/josejuanmartinez/2022-08-24-legre_whereas_en.md
docs/_posts/josejuanmartinez/2022-08-29-finner_headers_en.md
docs/_posts/josejuanmartinez/2022-08-30-finel_edgar_company_name_en.md
docs/_posts/josejuanmartinez/2022-08-30-finel_edgar_irs_en.md
docs/_posts/josejuanmartinez/2022-08-30-finmulticlf_news_en.md
docs/_posts/josejuanmartinez/2022-08-30-finner_bert_roles_en.md
docs/_posts/josejuanmartinez/2022-08-30-finner_org_per_role_date_en.md
docs/_posts/josejuanmartinez/2022-08-30-legel_edgar_company_name_en.md
docs/_posts/josejuanmartinez/2022-08-30-legel_edgar_irs_en.md
docs/_posts/josejuanmartinez/2022-08-30-legmulticlf_edgar_en.md
docs/_posts/josejuanmartinez/2022-08-31-finner_sec_conll_en.md
docs/_posts/josejuanmartinez/2022-08-31-finpipe_deid_en.md
docs/_posts/josejuanmartinez/2022-08-31-legpipe_deid_en.md
docs/_posts/josejuanmartinez/2022-09-02-finner_roberta_zeroshot_en.md
docs/_posts/josejuanmartinez/2022-09-02-legner_roberta_zeroshot_en.md
docs/_posts/josejuanmartinez/2022-09-06-finclf_augmented_esg_en.md
docs/_posts/josejuanmartinez/2022-09-06-finclf_bert_fls_en.md
docs/_posts/josejuanmartinez/2022-09-06-finclf_bert_sentiment_en.md
docs/_posts/josejuanmartinez/2022-09-06-finclf_esg_en.md
docs/_posts/josejuanmartinez/2022-09-07-finclf_bert_sentiment_phrasebank_en.md
docs/_posts/josejuanmartinez/2022-09-07-finvisualclf_vit_tickets_en.md
docs/_posts/josejuanmartinez/2022-09-07-legclf_bert_judgements_agent_en.md
docs/_posts/josejuanmartinez/2022-09-07-legclf_bert_judgements_argtype_en.md
docs/_posts/josejuanmartinez/2022-09-08-finel_names2tickers_en.md
docs/_posts/josejuanmartinez/2022-09-08-finre_acquisitions_subsidiaries_en.md
docs/_posts/josejuanmartinez/2022-09-09-finassertiondl_past_roles_en.md
docs/_posts/josejuanmartinez/2022-09-09-finel_tickers2names_en.md
docs/_posts/josejuanmartinez/2022-09-09-finpipe_org_per_role_date_en.md
docs/_posts/josejuanmartinez/2022-09-20-legclf_cuad_confidentiality_clause_en.md
docs/_posts/josejuanmartinez/2022-09-20-legclf_cuad_obligations_clause_en.md
docs/_posts/josejuanmartinez/2022-09-20-legclf_cuad_whereas_clause_en.md
docs/_posts/josejuanmartinez/2022-09-21-visualner_10kfilings_en.md
docs/_posts/josejuanmartinez/2022-09-21-visualner_keyvalue_10kfilings_en.md
docs/_posts/josejuanmartinez/2022-09-21-visualner_receipts_xx.md
docs/_posts/josejuanmartinez/2022-09-27-finassertion_time_en.md
docs/_posts/josejuanmartinez/2022-09-27-finner_bert_rufacts_ru.md
docs/_posts/josejuanmartinez/2022-09-27-legassertion_time_en.md
docs/_posts/josejuanmartinez/2022-09-27-legclf_cuad_indemnifications_clause_en.md
docs/_posts/josejuanmartinez/2022-09-27-legclf_cuad_licenses_clause_en.md
docs/_posts/josejuanmartinez/2022-09-27-legner_bert_indemnifications_en.md
docs/_posts/josejuanmartinez/2022-09-27-legner_br_base_pt.md
docs/_posts/josejuanmartinez/2022-09-27-legner_br_large_pt.md
docs/_posts/josejuanmartinez/2022-09-28-finclf_bert_banking77_en.md
docs/_posts/josejuanmartinez/2022-09-28-finre_work_experience_en.md
docs/_posts/josejuanmartinez/2022-09-28-legclf_enforceability_clause_en.md
docs/_posts/josejuanmartinez/2022-09-28-legclf_enforcement_clause_en.md
docs/_posts/josejuanmartinez/2022-09-28-legclf_environmental_matters_clause_en.md
docs/_posts/josejuanmartinez/2022-09-28-legner_br_bert_base_pt.md
docs/_posts/josejuanmartinez/2022-09-28-legner_br_bert_large_pt.md
docs/_posts/josejuanmartinez/2022-09-28-legner_law_money_es.md
docs/_posts/josejuanmartinez/2022-09-28-legner_laws_treaties_es.md
docs/_posts/josejuanmartinez/2022-09-28-legre_indemnifications_en.md
docs/_posts/josejuanmartinez/2022-10-02-legner_arabert_arabic_ar.md
docs/_posts/josejuanmartinez/2022-10-02-legner_bert_base_courts_de.md
docs/_posts/josejuanmartinez/2022-10-02-legner_bert_large_courts_de.md
docs/_posts/josejuanmartinez/2022-10-02-legner_courts_de.md
docs/_posts/josejuanmartinez/2022-10-18-legclf_cuad_warranty_clause_en.md
docs/_posts/josejuanmartinez/2022-10-19-finner_financial_medium_en.md
docs/_posts/josejuanmartinez/2022-10-19-finner_financial_small_en.md
docs/_posts/josejuanmartinez/2022-10-20-finner_financial_large_en.md
docs/_posts/josejuanmartinez/2022-10-22-finclf_bert_sentiment_analysis_lt.md
docs/_posts/josejuanmartinez/2022-10-22-finel_nasdaq_data_company_name_en.md
docs/_posts/josejuanmartinez/2022-10-22-finel_nasdaq_data_ticker_en.md
docs/_posts/josejuanmartinez/2022-10-22-finmapper_nasdaq_data_company_name_en.md
docs/_posts/josejuanmartinez/2022-10-22-finmapper_nasdaq_data_ticker_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_consulting_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_credit_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_employment_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_lease_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_loan_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_management_contract_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_purchase_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-24-legclf_service_agreement_en.md
docs/_posts/josejuanmartinez/2022-10-25-finner_sec_10k_summary_en.md
docs/_posts/kolia1985/2021-12-09-text_detection_v1_en.md
docs/_posts/kolia1985/2021-12-14-text_detection_v1_en.md
docs/_posts/kolia1985/2021-12-21-text_cleaner_v1_en.md
docs/_posts/kolia1985/2022-02-16-ocr_base_handwritten_en.md
docs/_posts/kolia1985/2022-02-16-ocr_small_printed_en.md
docs/_posts/kolia1985/2022-02-17-ocr_small_handwritten_en.md
docs/_posts/kolia1985/2022-06-15-ocr_base_handwritten_v2_en_3_0.md
docs/_posts/kolia1985/2022-07-16-layoutlmv3_finetuned_funsd_en_3_2.md
docs/_posts/luca-martial/2021-12-20-ner_drugprot_clinical_en.md
docs/_posts/luca-martial/2022-01-05-re_drugprot_clinical_en.md
docs/_posts/luca-martial/2022-01-05-redl_drugprot_biobert_en.md
docs/_posts/luca-martial/2022-02-07-bert_sequence_classifier_pico_biobert_en.md
docs/_posts/luca-martial/2022-02-08-bert_sequence_classifier_ade_en.md
docs/_posts/luca-martial/2022-02-08-bert_sequence_classifier_gender_biobert_en.md
docs/_posts/luca-martial/2022-02-08-distilbert_sequence_classifier_ade_en.md
docs/_posts/luca-martial/2022-02-11-ner_deid_generic_fr.md
docs/_posts/luca-martial/2022-02-11-ner_deid_subentity_fr.md
docs/_posts/luca-martial/2022-02-14-ner_deid_subentity_fr.md
docs/_posts/luca-martial/2022-02-23-clinical_deidentification_fr.md
docs/_posts/luca-martial/2022-03-04-clinical_deidentification_fr_2_4.md
docs/_posts/luca-martial/2022-03-22-ner_deid_subentity_it_3_0.md
docs/_posts/luca-martial/2022-03-25-ner_deid_generic_it_2_4.md
docs/_posts/luca-martial/2022-03-25-ner_deid_generic_it_3_0.md
docs/_posts/luca-martial/2022-03-25-ner_deid_subentity_it_2_4.md
docs/_posts/luca-martial/2022-03-28-clinical_deidentification_it_2_4.md
docs/_posts/luca-martial/2022-03-28-clinical_deidentification_it_3_0.md
docs/_posts/luca-martial/2022-06-22-ner_clinical_trials_abstracts_en_3_0.md
docs/_posts/luca-martial/2022-06-29-bert_token_classifier_ner_clinical_trials_abstracts_en_3_0.md
docs/_posts/luca-martial/2022-07-08-clinical_deidentification_wip_en_3_0.md
docs/_posts/luca-martial/2022-07-24-clinical_deidentification_en_3_0.md
docs/_posts/luca-martial/2022-07-24-clinical_deidentification_slim_en_3_0.md
docs/_posts/mauro-nievoff/2022-07-25-assertion_oncology_treatment_binary_wip_en_3_0.md
docs/_posts/mauro-nievoff/2022-07-25-ner_oncology_wip_en_3_0.md
docs/_posts/mauro-nievoff/2022-09-26-re_oncology_size_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_biomarker_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_granular_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_location_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_temporal_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_test_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-09-28-redl_oncology_size_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biomarker_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_granular_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_location_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_temporal_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_test_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_anatomy_general_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_demographics_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_diagnosis_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_test_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_therapy_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_tnm_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_unspecific_posology_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_test_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_anatomy_granular_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_biomarker_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_posology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_wip_en.md
docs/_posts/muhammetsnts/2021-04-30-ner_jsl_en.md
docs/_posts/muhammetsnts/2021-05-02-snomed_icd10cm_mapping_en.md
docs/_posts/muhammetsnts/2021-05-04-icd10cm_umls_mapping_en.md
docs/_posts/muhammetsnts/2021-05-04-mesh_umls_mapping_en.md
docs/_posts/muhammetsnts/2021-05-04-rxnorm_mesh_mapping_en.md
docs/_posts/muhammetsnts/2021-05-04-rxnorm_umls_mapping_en.md
docs/_posts/muhammetsnts/2021-05-04-snomed_umls_mapping_en.md
docs/_posts/muhammetsnts/2021-05-25-sbertresolve_icd10cm_slim_billable_hcc_med_en.md
docs/_posts/muhammetsnts/2021-05-25-sbiobertresolve_icd10cm_slim_billable_hcc_en.md
docs/_posts/muhammetsnts/2021-05-27-clinical_deidentification_en.md
docs/_posts/muhammetsnts/2021-06-01-redl_bodypart_direction_biobert_en.md
docs/_posts/muhammetsnts/2021-06-01-redl_bodypart_problem_biobert_en.md
docs/_posts/muhammetsnts/2021-06-01-redl_bodypart_procedure_test_biobert_en.md
docs/_posts/muhammetsnts/2021-06-01-redl_date_clinical_biobert_en.md
docs/_posts/muhammetsnts/2021-06-08-clinical_deidentification_glove_en.md
docs/_posts/muhammetsnts/2021-06-15-sbertresolve_snomed_bodyStructure_med_en.md
docs/_posts/muhammetsnts/2021-06-15-sbiobertresolve_cpt_procedures_augmented_en.md
docs/_posts/muhammetsnts/2021-06-15-sbiobertresolve_snomed_bodyStructure_en.md
docs/_posts/muhammetsnts/2021-06-15-sbiobertresolve_snomed_findings_en.md
docs/_posts/muhammetsnts/2021-06-21-ner_jsl_en.md
docs/_posts/muhammetsnts/2021-06-21-ner_jsl_greedy_en.md
docs/_posts/muhammetsnts/2021-06-22-sbiobertresolve_icdo_augmented_en.md
docs/_posts/muhammetsnts/2021-06-24-ner_jsl_en.md
docs/_posts/muhammetsnts/2021-06-24-ner_jsl_greedy_en.md
docs/_posts/muhammetsnts/2021-06-25-ner_genetic_variants_en.md
docs/_posts/muhammetsnts/2021-07-08-sbertresolve_snomed_bodyStructure_med_en.md
docs/_posts/muhammetsnts/2021-07-08-sbiobertresolve_snomed_bodyStructure_en.md
docs/_posts/muhammetsnts/2021-07-14-sbiobertresolve_snomed_findings_aux_concepts_en.md
docs/_posts/muhammetsnts/2021-07-24-assertion_jsl_en.md
docs/_posts/muhammetsnts/2021-07-24-assertion_jsl_large_en.md
docs/_posts/muhammetsnts/2021-07-24-redl_chemprot_biobert_en.md
docs/_posts/muhammetsnts/2021-07-24-redl_clinical_biobert_en.md
docs/_posts/muhammetsnts/2021-07-24-redl_drug_drug_interaction_biobert_en.md
docs/_posts/muhammetsnts/2021-07-24-redl_human_phenotype_gene_biobert_en.md
docs/_posts/muhammetsnts/2021-07-24-redl_temporal_events_biobert_en.md
docs/_posts/muhammetsnts/2021-08-12-sbiobertresolve_rxnorm_disposition_en.md
docs/_posts/muhammetsnts/2021-08-13-ner_jsl_greedy_biobert_en.md
docs/_posts/muhammetsnts/2021-08-26-sbertresolve_icd10cm_slim_billable_hcc_med_en.md
docs/_posts/muhammetsnts/2021-08-26-sbiobertresolve_icd10cm_slim_billable_hcc_en.md
docs/_posts/muhammetsnts/2021-08-28-bert_token_classifier_ner_clinical_en.md
docs/_posts/muhammetsnts/2021-08-28-bert_token_classifier_ner_jsl_en.md
docs/_posts/muhammetsnts/2021-08-28-sbertresolve_rxnorm_disposition_en.md
docs/_posts/muhammetsnts/2021-08-28-sbertresolve_snomed_conditions_en.md
docs/_posts/muhammetsnts/2021-09-15-ner_healthcare_de.md
docs/_posts/muhammetsnts/2021-09-15-spellcheck_drug_norvig_en.md
docs/_posts/muhammetsnts/2021-09-16-sbertresolve_icd10gm_de.md
docs/_posts/muhammetsnts/2021-09-16-sbertresolve_snomed_de.md
docs/_posts/muhammetsnts/2021-09-23-ner_profiling_biobert_en.md
docs/_posts/muhammetsnts/2021-09-24-ner_profiling_clinical_en.md
docs/_posts/muhammetsnts/2021-09-29-sbiobertresolve_hcpcs_en.md
docs/_posts/muhammetsnts/2021-10-05-sbiobertresolve_rxnorm_ndc_en.md
docs/_posts/muhammetsnts/2021-10-10-sbiobertresolve_rxnorm_en.md
docs/_posts/muhammetsnts/2021-10-31-sbiobertresolve_icd10cm_augmented_en.md
docs/_posts/muhammetsnts/2021-11-01-sbiobertresolve_icd10cm_augmented_billable_hcc_en.md
docs/_posts/muhammetsnts/2021-11-03-ner_profiling_biobert_en.md
docs/_posts/muhammetsnts/2021-11-03-ner_profiling_clinical_en.md
docs/_posts/muhammetsnts/2021-11-14-sbiobertresolve_mesh_en.md
docs/_posts/muhammetsnts/2021-11-24-ner_model_finder_en.md
docs/_posts/muhammetsnts/2021-11-24-sbertresolve_ner_model_finder_en.md
docs/_posts/muhammetsnts/2021-11-27-sbiobertresolve_ndc_en.md
docs/_posts/muhammetsnts/2021-12-11-sbiobertresolve_clinical_abbreviation_acronym_en.md
docs/_posts/muhammetsnts/2021-12-22-icd10_icd9_mapping_en.md
docs/_posts/muhammetsnts/2021-12-30-ner_abbreviation_clinical_en.md
docs/_posts/muhammetsnts/2022-01-01-sbiobertresolve_snomed_drug_en.md
docs/_posts/muhammetsnts/2022-01-03-sbiobertresolve_clinical_abbreviation_acronym_en.md
docs/_posts/muhammetsnts/2022-06-28-bert_sequence_classifier_stress_en_3_0.md
docs/_posts/muhammetsnts/2022-07-25-bert_sequence_classifier_health_mentions_en_3_0.md
docs/_posts/muhammetsnts/2022-07-25-classifierdl_health_mentions_en_3_0.md
docs/_posts/muhammetsnts/2022-07-27-bert_sequence_classifier_stressor_en_3_0.md
docs/_posts/muhammetsnts/2022-07-28-bert_sequence_classifier_vaccine_sentiment_en_3_0.md
docs/_posts/muhammetsnts/2022-08-28-ner_profiling_biobert_en.md
docs/_posts/muhammetsnts/2022-08-29-zero_shot_ner_roberta_en.md
docs/_posts/muhammetsnts/2022-08-30-ner_profiling_clinical_en.md
docs/_posts/muhammetsnts/2022-09-05-ner_model_finder_en.md
docs/_posts/muhammetsnts/2022-09-05-sbertresolve_ner_model_finder_en.md
docs/_posts/murat-gunay/2020-09-01-posology_re.md
docs/_posts/murat-gunay/2021-03-18-assertion_dl_radiology_en.md
docs/_posts/murat-gunay/2021-06-01-ner_deid_generic_augmented_en.md
docs/_posts/murat-gunay/2021-06-06-ner_deid_generic_glove_en.md
docs/_posts/murat-gunay/2021-06-06-ner_deid_subentity_glove_en.md
docs/_posts/murat-gunay/2021-09-03-ner_deid_subentity_augmented_en.md
docs/_posts/murat-gunay/2021-09-13-bert_token_classifier_ner_deid_en.md
docs/_posts/murat-gunay/2021-09-16-bert_token_classifier_ner_jsl_en.md
docs/_posts/murat-gunay/2021-09-20-bert_token_classifier_ner_drugs_en.md
docs/_posts/murat-gunay/2021-09-24-bert_token_classifier_ner_jsl_slim_en.md
docs/_posts/murat-gunay/2021-09-30-bert_token_classifier_ner_ade_en.md
docs/_posts/murat-gunay/2021-09-30-bert_token_classifier_ner_anatomy_en.md
docs/_posts/murat-gunay/2021-09-30-bert_token_classifier_ner_bacteria_en.md
docs/_posts/murat-gunay/2021-10-19-bert_token_classifier_ner_chemicals_en.md
docs/_posts/murat-gunay/2021-10-19-bert_token_classifier_ner_chemprot_en.md
docs/_posts/murat-gunay/2021-11-03-bert_token_classifier_ner_bionlp_en.md
docs/_posts/murat-gunay/2021-11-03-bert_token_classifier_ner_cellular_en.md
docs/_posts/murat-gunay/2021-11-04-ner_chemd_clinical_en.md
docs/_posts/murat-gunay/2021-11-29-ner_deid_subentity_augmented_i2b2_en.md
docs/_posts/murat-gunay/2022-03-09-bert_token_classifier_ner_cellular_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-10-bert_token_classifier_ner_cellular_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-03-14-bert_token_classifier_ner_chemicals_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-03-14-bert_token_classifier_ner_chemicals_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-15-bert_token_classifier_ner_chemprot_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-03-15-bert_token_classifier_ner_chemprot_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-15-bert_token_classifier_ner_clinical_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-03-15-bert_token_classifier_ner_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_ade_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_anatomy_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_bacteria_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_bionlp_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_cellular_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_chemicals_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_chemprot_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_deid_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_drugs_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-bert_token_classifier_ner_jsl_slim_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_ner_wip_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_ner_wip_greedy_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_ner_wip_greedy_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_ner_wip_modifier_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_rd_ner_wip_greedy_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-jsl_rd_ner_wip_greedy_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_abbreviation_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_ade_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_ade_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_ade_clinicalbert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_anatomy_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_anatomy_coarse_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_anatomy_coarse_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_anatomy_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_bacterial_species_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_biomarker_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_bionlp_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_bionlp_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_cancer_genetics_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_cellular_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_cellular_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_chemicals_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_chemprot_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_chemprot_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_chexpert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_clinical_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_clinical_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_augmented_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_enriched_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_enriched_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_generic_augmented_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_generic_pipeline_de_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_sd_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_sd_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_subentity_augmented_i2b2_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_subentity_augmented_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deid_subentity_pipeline_de_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_deidentify_dl_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_diseases_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_diseases_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_diseases_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_drugprot_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_drugs_greedy_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_drugs_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_drugs_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_events_admission_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_events_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_events_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_genetic_variants_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_human_phenotype_gene_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_human_phenotype_gene_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_human_phenotype_go_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_human_phenotype_go_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_enriched_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_enriched_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_greedy_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_greedy_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_jsl_slim_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_measurements_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_medmentions_coarse_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_nihss_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_experimental_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_greedy_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_large_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_large_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_posology_small_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_radiology_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_radiology_wip_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_risk_factors_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_risk_factors_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_ade_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_events_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_posology_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-23-bert_token_classifier_drug_development_trials_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-23-bert_token_classifier_ner_jsl_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_bodypart_directions_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_bodypart_proceduretest_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_date_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_human_phenotype_gene_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_temporal_events_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_temporal_events_enriched_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_test_problem_finding_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_test_result_date_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-04-11-spellcheck_clinical_en_3_0.md
docs/_posts/murat-gunay/2022-04-13-spellcheck_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-04-14-spellcheck_clinical_en_2_4.md
docs/_posts/murat-gunay/2022-04-14-spellcheck_clinical_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-04-18-spellcheck_clinical_en_2_4.md
docs/_posts/murat-gunay/2022-04-19-spellcheck_clinical_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-05-10-ner_biomedical_bc2gm_en_3_0.md
docs/_posts/murat-gunay/2022-05-11-ner_biomedical_bc2gm_en_2_4.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_afriberta_base_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_afriberta_large_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_afriberta_small_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_cino_base_v2_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_cino_large_v2_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_cino_small_v2_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_fairlex_cail_minilm_zh_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_fairlex_fscs_minilm_xx_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_indic_transformers_bn_xlmroberta_bn_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_indic_transformers_hi_xlmroberta_hi_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_indic_transformers_te_xlmroberta_te_3_0.md
docs/_posts/murat-gunay/2022-05-13-xlmroberta_embeddings_marathi_roberta_mr_3_0.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_bert_subentity_ro_3_0.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_subentity_bert_ro_3_0.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_subentity_ro_3_0.md
docs/_posts/murat-gunay/2022-06-27-ner_deid_w2v_subentity_ro_3_0.md
docs/_posts/murat-gunay/2022-07-06-ner_deid_generic_bert_ro_3_0.md
docs/_posts/murat-gunay/2022-07-08-ner_deid_generic_ro_3_0.md
docs/_posts/xusliebana/2021-01-29-deidentify_enriched_clinical_en.md
docs/_posts/xyutech/2021-09-04-ocr_table_detection_general_model_en.md
docs/_posts/xyutech/2021-12-30-layoutlmv2_funsd_en.md
docs/_posts/xyutech/2022-01-05-layoutlmv2_funsd_en.md
docs/_posts/xyutech/2022-06-09-dit_base_finetuned_rvlcdip_en_3_0.md
docs/_posts/xyutech/2022-06-12-dit_base_finetuned_rvlcdip_en_2_4.md
docs/_posts/xyutech/2022-07-20-layoutlmv2_rvl_cdip_40k_en_3_0.md
